Netherton syndrome

Mendelian MONDO:0009735 Pathograph 17 inherited ichthyosis genodermatosis

Netherton syndrome is a rare autosomal recessive inherited ichthyosis caused by SPINK5 loss-of-function variants, with resulting LEKTI deficiency, epidermal barrier dysfunction, chronic skin inflammation, and prominent atopic features.

Ask OpenScientist

Ask a research question about Netherton syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
9
Pathophys.
7
Phenotypes
17
Pathograph
1
Genes
9
Medical Actions
2
Subtypes
5
Differentials
2
Datasets
3
Trials
1
Deep Research
🏷

Classifications

Harrison's Chapter
DERMATOLOGY GENETICS_ENVIRONMENT_DISEASE
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
Autosomal recessive inheritance
Show evidence (1 reference)
PMID:27905021 SUPPORT Human Clinical
"Netherton syndrome (OMIM #256500) is a rare but severe autosomal recessive form of ichthyosis that affects the skin, hair, and immune system."
This review explicitly states the autosomal recessive inheritance mode for Netherton syndrome.
◆

Subtypes

2
Ichthyosiform erythroderma-predominant Netherton syndrome
Clinical subtype with persistent diffuse erythroderma and ichthyosiform scaling.
Show evidence (1 reference)
PMID:38634098 SUPPORT Human Clinical
"There are two subtypes of the syndrome that differ in clinical presentation and immune profile: ichthyosiform erythroderma and ichthyosis linearis circumflexa."
This supports ichthyosiform erythroderma as one recognized clinical subtype of NS.
Ichthyosis linearis circumflexa-predominant Netherton syndrome
Clinical subtype characterized by migratory polycyclic erythematous plaques with characteristic double-edged scale.
Show evidence (1 reference)
PMID:38634098 SUPPORT Human Clinical
"There are two subtypes of the syndrome that differ in clinical presentation and immune profile: ichthyosiform erythroderma and ichthyosis linearis circumflexa."
This supports ichthyosis linearis circumflexa as a second recognized clinical subtype of NS.
⚙

Pathophysiology

9
SPINK5 loss-of-function variants
Biallelic pathogenic SPINK5 variants reduce functional SPINK5 output and initiate Netherton syndrome pathogenesis.
keratinocyte CL:0000312
SPINK5 hgnc:15464
skin epidermis UBERON:0001003
Downstream
LEKTI protein deficiency SPINK5 loss of function reduces or abolishes LEKTI protein levels.
Show evidence (2 references)
DOI:10.1038/s42003-024-05780-y SUPPORT Model Organism
"AbstractNetherton syndrome (NS) is a rare skin disease caused by loss-of-function mutations in the serine peptidase inhibitor Kazal type 5 (SPINK5) gene."
This supports SPINK5 loss of function as the initiating lesion in NS.
PMID:40607310 SUPPORT Human Clinical
"Netherton syndrome (NS) is a rare autosomal recessive genodermatosis caused by pathogenic mutations in the serine protease inhibitor Kazal-type 5 (SPINK5) gene, leading to impaired skin barrier function and immune dysregulation."
This supports pathogenic SPINK5 variants as the primary molecular driver in human NS.
LEKTI protein deficiency
Reduced or absent LEKTI removes a key epidermal serine-protease brake in skin and hair-bearing epithelium.
keratinocyte CL:0000312
skin epidermis UBERON:0001003
Downstream
Unchecked epidermal kallikrein protease activity LEKTI deficiency permits excessive epidermal serine protease activity.
Hair shaft structural fragility from follicular protease imbalance LEKTI loss in hair follicles predisposes to bamboo-hair morphology.
Show evidence (1 reference)
DOI:10.3390/genes14051080 SUPPORT Human Clinical
"Netherton syndrome (NS) is a rare autosomal recessive disorder caused by SPINK5 mutations, resulting in a deficiency in its processed protein LEKTI."
This supports LEKTI deficiency as a distinct downstream molecular consequence of SPINK5 defects.
Unchecked epidermal kallikrein protease activity
Loss of LEKTI control leads to increased epidermal protease activity, including KLK-dependent proteolysis in the stratum corneum.
keratinocyte CL:0000312
proteolysis GO:0006508
stratum corneum of epidermis UBERON:0002027
Downstream
Corneodesmosome degradation and accelerated desquamation Excessive proteolysis promotes premature corneocyte detachment.
KLK-mediated IL-36 cytokine processing KLKs proteolytically activate IL-36 family pro-cytokines.
Show evidence (2 references)
DOI:10.1038/s42003-024-05780-y SUPPORT Model Organism
"Spink5 cKO mice and NS patients share skin barrier and inflammation signatures defined by up-regulation and increased activity of proteases, IL-17, IL-36, and IL-20 family cytokine signaling."
This supports increased protease activity as a central intermediary event in NS.
DOI:10.1038/s42003-024-05780-y SUPPORT Model Organism
"By comparing skin transcriptomes and proteomes, we uncover several putative substrates of tissue kallikrein-related proteases (KLKs), demonstrating that KLKs can proteolytically regulate IL-36 pro-inflammatory cytokines."
This directly supports KLK-driven IL-36 cytokine processing.
Corneodesmosome degradation and accelerated desquamation
Excess serine-protease activity accelerates stratum corneum protein breakdown, causing premature shedding and unstable cornified layers.
proteolysis GO:0006508 keratinization GO:0031424
stratum corneum of epidermis UBERON:0002027
Downstream
Epidermal barrier breakdown and increased transepidermal water loss Corneocyte cohesion failure impairs the physical epidermal barrier.
Ichthyosis Disordered cornification and scaling manifest clinically as ichthyosis.
Show evidence (1 reference)
DOI:10.1038/s42003-024-05780-y SUPPORT Model Organism
"Spink5 cKO mice and NS patients share skin barrier and inflammation signatures defined by up-regulation and increased activity of proteases, IL-17, IL-36, and IL-20 family cytokine signaling."
This supports protease-driven barrier/cornification pathology in NS.
Epidermal barrier breakdown and increased transepidermal water loss
Defective stratum corneum integrity increases permeability to water, allergens, and microbes, establishing chronic barrier failure.
keratinocyte CL:0000312
keratinization GO:0031424
skin epidermis UBERON:0001003
Downstream
Enhanced cutaneous entry of allergens and microbes Increased permeability raises exposure to environmental antigens and pathogens.
Recurrent infections Barrier failure contributes to repeated skin and systemic infections.
Pruritus Barrier disruption drives itch through xerosis and neuroimmune activation.
Show evidence (2 references)
DOI:10.1038/s42003-024-05780-y SUPPORT Model Organism
"Spink5 cKO mice and NS patients share skin barrier and inflammation signatures defined by up-regulation and increased activity of proteases, IL-17, IL-36, and IL-20 family cytokine signaling."
This supports barrier dysfunction as a key pathophysiologic hub in NS.
PMID:38025195 SUPPORT Human Clinical
"Loss of LEKTI induces severe skin barrier defect."
This provides additional human case-level support for severe barrier disruption in NS.
KLK-mediated IL-36 cytokine processing
KLK proteases cleave IL-36 cytokine precursors, amplifying epidermal pro-inflammatory signaling.
inflammatory response GO:0006954
Downstream
IL-17/IL-36 inflammatory amplification IL-36 signaling feeds forward into chronic inflammatory circuits.
Show evidence (2 references)
DOI:10.1038/s42003-024-05780-y SUPPORT Model Organism
"By comparing skin transcriptomes and proteomes, we uncover several putative substrates of tissue kallikrein-related proteases (KLKs), demonstrating that KLKs can proteolytically regulate IL-36 pro-inflammatory cytokines."
This defines the KLK-to-IL-36 activation step in the NS inflammatory cascade.
DOI:10.3390/dermatopathology11030024 SUPPORT Human Clinical
"Both cases demonstrated robust expression of IL-36."
This supports IL-36 pathway activation in NS patient skin biopsies.
Enhanced cutaneous entry of allergens and microbes
Persistent barrier failure promotes antigen penetration and microbial exposure, increasing both atopic sensitization and infection vulnerability.
inflammatory response GO:0006954
Downstream
IL-17/IL-36 inflammatory amplification Antigen and microbe exposure sustains chronic inflammatory signaling.
Atopic dermatitis Cutaneous allergen entry contributes to severe eczematous disease.
Recurrent infections Reduced barrier defense promotes repeated infectious episodes.
Show evidence (1 reference)
PMID:41126693 SUPPORT Human Clinical
"Netherton syndrome (NTS) is a syndromic ichthyosis characterized by scaling, erythroderma, and proneness towards allergies and infections."
This supports concurrent allergy-prone and infection-prone consequences of barrier failure.
IL-17/IL-36 inflammatory amplification
Combined IL-36 and IL-17 pathway activation sustains epidermal inflammation and drives persistent erythro-inflammatory and eczematous disease.
inflammatory response GO:0006954 interleukin-17-mediated signaling pathway GO:0097400
Downstream
Erythroderma High inflammatory burden produces diffuse erythema and scaling.
Atopic dermatitis Chronic cytokine activation drives eczematous inflammation.
Pruritus Cytokine-mediated neuroimmune signaling contributes to severe itch.
Failure to thrive Sustained systemic inflammatory burden can impair growth in severe disease.
Show evidence (2 references)
DOI:10.1038/s42003-024-05780-y SUPPORT Model Organism
"Spink5 cKO mice and NS patients share skin barrier and inflammation signatures defined by up-regulation and increased activity of proteases, IL-17, IL-36, and IL-20 family cytokine signaling."
This supports IL-17/IL-36 axis overactivation as a core inflammatory driver in NS.
DOI:10.3390/dermatopathology11030024 SUPPORT Human Clinical
"Both cases demonstrated robust expression of IL-36."
This provides patient-level biopsy support for IL-36-driven inflammation.
Hair shaft structural fragility from follicular protease imbalance
SPINK5/LEKTI dysfunction in hair-bearing epithelium contributes to defective hair-shaft integrity, including trichorrhexis invaginata susceptibility.
keratinocyte CL:0000312
SPINK5 hgnc:15464
keratinization GO:0031424
Downstream
Hair shaft abnormality Follicular structural defects manifest as bamboo hair and related shaft anomalies.
Show evidence (1 reference)
DOI:10.3390/genes14051080 SUPPORT Human Clinical
"It is clinically characterized by the triad of congenital ichthyosis, atopic diathesis, and hair shaft abnormalities."
This supports hair-shaft defects as a direct disease consequence within the SPINK5/LEKTI mechanism.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Netherton syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

7
Immune 3
Erythroderma Erythroderma HP:0001019
Show evidence (2 references)
PMID:41126693 SUPPORT Human Clinical
"Netherton syndrome (NTS) is a syndromic ichthyosis characterized by scaling, erythroderma, and proneness towards allergies and infections."
This explicitly reports erythroderma as a characteristic phenotype in NS.
PMID:40299794 SUPPORT Human Clinical
"Physical examination showed generalized erythroderma and polycyclic and serpiginous erythematous plaques with double-edged scales at the margins."
This case report provides direct clinical evidence for erythroderma in NS.
Atopic dermatitis Atopic dermatitis HP:0001047
Show evidence (2 references)
DOI:10.3390/genes14051080 SUPPORT Human Clinical
"We describe an NS patient, initially misdiagnosed with severe AD, who carried the heterozygous frameshift (null) mutation (NM_006846.4): c.957_960dup combined with homozygous rs2303067 in the SPINK5 gene."
This supports atopic-dermatitis-like presentations and diagnostic overlap in NS.
PMID:40299794 SUPPORT Human Clinical
"The patient was previously diagnosed with atopic dermatitis and had been treated with systemic corticosteroids and omalizumab, without improvement."
This supports frequent diagnostic overlap and initial misclassification as severe atopic dermatitis.
Recurrent infections Recurrent infections HP:0002719
Show evidence (2 references)
PMID:41126693 SUPPORT Human Clinical
"Netherton syndrome (NTS) is a syndromic ichthyosis characterized by scaling, erythroderma, and proneness towards allergies and infections."
This supports recurrent infection susceptibility as part of the NS phenotype spectrum.
PMID:40607310 SUPPORT Human Clinical
"The patient was treated with intravenous immunoglobulin due to frequent infections that required multiple hospital admissions."
This provides direct case-level evidence for recurrent severe infections in NS.
Integument 3
Ichthyosis Ichthyosis HP:0008064
Show evidence (1 reference)
DOI:10.3390/genes14051080 SUPPORT Human Clinical
"It is clinically characterized by the triad of congenital ichthyosis, atopic diathesis, and hair shaft abnormalities."
This directly supports ichthyosis as a core clinical manifestation of NS.
Hair shaft abnormality Abnormal hairshaft morphology HP:0003328
Show evidence (2 references)
DOI:10.3390/genes14051080 SUPPORT Human Clinical
"It is clinically characterized by the triad of congenital ichthyosis, atopic diathesis, and hair shaft abnormalities."
This supports hair-shaft abnormalities as a core component of the NS clinical triad.
PMID:40299794 SUPPORT Human Clinical
"Trichoscopy of the scalp revealed a hair shaft abnormality, specifically trichorrhexis invaginata."
This provides direct clinical confirmation of characteristic bamboo-hair morphology in NS.
Pruritus Pruritus HP:0000989
Show evidence (2 references)
clinicaltrials:NCT04244006 SUPPORT Human Clinical
"To date, there are no effective therapy for the management of Netherton Syndrome (NS) Patients use emollients with a limited efficacy on scaling and no efficacy on skin inflammation and pruritus."
Trial summary explicitly identifies pruritus as a persistent symptom and treatment target.
PMID:40607310 SUPPORT Human Clinical
"He demonstrated substantial clinical benefits, with marked relief from pruritus resulting in better quality of life."
This supports that pruritus is a major and treatment-responsive symptomatic burden in NS.
Growth 1
Failure to thrive Failure to thrive HP:0001508
Show evidence (2 references)
PMID:39931731 SUPPORT Human Clinical
"We observed that patients with variants or homozygous variants located in the 5' half of the gene were more likely to experience failure to thrive (P < 0.05)."
This supports genotype-associated risk of failure to thrive in NS cohorts.
PMID:38634098 SUPPORT Human Clinical
"We describe an 8-year-old boy with genetically proven NS treated with intravenous immunoglobulin for recurrent skin and systemic infections from infancy, growth retardation, and associated erythroderma."
This supports growth retardation/failure-to-thrive manifestations in pediatric NS.
🧬

Genetic Associations

1
SPINK5 (Causative)
Gene: SPINK5 hgnc:15464
Show evidence (6 references)
DOI:10.3390/genes14051080 SUPPORT Human Clinical
"Netherton syndrome (NS) is a rare autosomal recessive disorder caused by SPINK5 mutations, resulting in a deficiency in its processed protein LEKTI."
This directly supports SPINK5 as the causal gene and links genotype to LEKTI deficiency.
PMID:27905021 SUPPORT Human Clinical
"The identification of SPINK5, which encodes for the serine protease inhibitor LEKTI, as the gene responsible for Netherton syndrome, enabled the search for causative mutations in Netherton syndrome patients and families."
This supports SPINK5 as the established disease gene and highlights genotype-phenotype analysis in affected families.
PMID:39931731 SUPPORT Human Clinical
"Among 162 patients, we identified 324 allele variants, comprising 75 different mutations."
This supports broad allelic heterogeneity and the need for comprehensive SPINK5 variant interpretation.
+ 3 more references
💊

Medical Actions

9
Supportive topical skin care
Action: supportive care MAXO:0000950
Emollients and topical anti-inflammatory therapy remain baseline management for scaling and eczematous inflammation, though control is often incomplete.
Show evidence (1 reference)
clinicaltrials:NCT04244006 SUPPORT Human Clinical
"To date, there are no effective therapy for the management of Netherton Syndrome (NS) Patients use emollients with a limited efficacy on scaling and no efficacy on skin inflammation and pruritus."
This trial summary supports current reliance on topical supportive care and its limitations.
Ex vivo SPINK5 gene-corrected epidermal sheet grafting (investigational)
Action: gene therapy MAXO:0001001
Phase I ex vivo lentiviral gene therapy strategy using autologous epidermal sheets generated from genetically modified skin stem cells to restore LEKTI in Netherton syndrome.
Show evidence (2 references)
clinicaltrials:NCT01545323 SUPPORT Human Clinical
"The investigators have used a disabled virus (vector) to carry a functional copy of the SPINK5 gene into skin stem cells."
This supports an ex vivo lentiviral SPINK5 gene-correction strategy in NS.
clinicaltrials:NCT01545323 SUPPORT Human Clinical
"In this trial the investigators propose grafting of autologous epidermal sheets generated from genetically modified skin stem cells for the treatment of patients with Netherton Syndrome."
This supports autologous epidermal sheet grafting from genetically corrected skin stem cells as the investigational treatment approach.
Cytokine-targeted systemic pharmacotherapy
Action: Pharmacotherapy NCIT:C15986
Agent: dupilumab NCIT:C162455 secukinumab NCIT:C152315 abrocitinib NCIT:C166985
Biologics and JAK inhibitors are emerging options in severe disease, targeting IL-4/IL-13, IL-17, IL-36, and JAK pathways.
Show evidence (3 references)
PMID:40888388 SUPPORT Human Clinical
"This review provides a comprehensive overview of the current clinical landscape and future directions of biologics (e.g., dupilumab, secukinumab, ustekinumab) and small-molecule therapies (e.g., JAK inhibitors such as tofacitinib, baricitinib, and upadacitinib) in the treatment of NS."
This supports use of cytokine-targeted and JAK-pathway therapies in severe NS.
PMID:40888388 PARTIAL Human Clinical
"Though evidence remains limited to case reports and small series, preliminary data suggest that cytokine-targeted interventions-particularly those inhibiting IL-4, IL-13, IL-17, IL-36, and JAK pathways-may offer tangible clinical benefits."
This supports potential efficacy while acknowledging current evidence limits.
PMID:40969297 SUPPORT Human Clinical
"Both patients had swift and enduring enhancement of skin lesions during the follow-up period."
This case series adds contemporary human evidence that biologic pathway targeting can improve NS skin disease.
Immunoglobulin and biologic systemic therapy
Action: intravenous immunoglobulin therapy Ontology label: immunoglobulin infusion therapy MAXO:0001480
Agent: dupilumab NCIT:C162455 secukinumab NCIT:C152315
Systematic review data indicate skin improvement in many reported cases with immunoglobulins and biologics.
Show evidence (2 references)
PMID:35464459 SUPPORT Human Clinical
"Immunoglobulins (13/15 cases) and biologicals (18/21 cases) showed improvement of the skin."
This supports observed skin benefit in aggregated case-based treatment evidence.
PMID:38634098 SUPPORT Human Clinical
"Under this therapy, his skin status, infectious exacerbations, and quality of life all improved."
This provides additional pediatric case-level support for IVIG-centered systemic therapy.
Intravenous immunoglobulin (IVIG) for infection-prone pediatric NS
Action: intravenous immunoglobulin therapy Ontology label: immunoglobulin infusion therapy MAXO:0001480
High-dose IVIG has been used in children with recurrent skin/systemic infections and severe inflammatory skin disease, with reported improvement in skin status and infectious exacerbations.
Show evidence (2 references)
PMID:38634098 SUPPORT Human Clinical
"KEY CLINICAL MESSAGE: High-dose intravenous immunoglobulin exhibits great potential in the treatment of Netherton syndrome."
This explicitly supports IVIG as a promising strategy in pediatric NS.
PMID:40607310 SUPPORT Human Clinical
"The patient was treated with intravenous immunoglobulin due to frequent infections that required multiple hospital admissions."
This supports IVIG use in infection-prone NS with severe recurrent admissions.
Dupilumab (IL-4/IL-13 pathway inhibition)
Action: biologic therapy Ontology label: Immunotherapy NCIT:C15262
Agent: dupilumab NCIT:C162455
Dupilumab has shown improvement in pruritus and inflammatory skin disease in pediatric and mixed-age NS case reports/series.
Show evidence (3 references)
PMID:40607310 SUPPORT Human Clinical
"When he was 6 years old, dupilumab was added to reduce skin inflammation and improve skin barrier function before food reintroduction."
This supports dupilumab targeting inflammatory and barrier manifestations in pediatric NS.
PMID:40969297 SUPPORT Human Clinical
"The child received treatment with dupilumab, while the 19-year-old woman alternated between using dupilumab and secukinumab."
This supports real-world use of dupilumab across pediatric and young-adult NS cases.
PMID:35327681 SUPPORT Human Clinical
"Since treatment with various antihistamines were not effective, we administered dupilumab and found that it was effective in immediate elimination of pruritus and gradual reduction of the rash."
This adds additional case-level evidence for dupilumab benefit on pruritus and inflammatory skin burden.
Secukinumab (IL-17 pathway inhibition)
Action: biologic therapy Ontology label: Immunotherapy NCIT:C15262
Agent: secukinumab NCIT:C152315
IL-17A blockade with secukinumab has shown clinical improvement in refractory NS in case-level evidence.
Show evidence (2 references)
PMID:40299794 SUPPORT Human Clinical
"After 2 injections, the patient's condition markedly improved and the effect after the last injection was maintained for 4-5 months."
This supports clinically meaningful short-term and sustained response to secukinumab in refractory NS.
PMID:40969297 SUPPORT Human Clinical
"The child received treatment with dupilumab, while the 19-year-old woman alternated between using dupilumab and secukinumab."
This supports secukinumab use as part of targeted biologic treatment strategies in NS.
Abrocitinib (JAK1 inhibitor)
Action: Pharmacotherapy NCIT:C15986
Agent: abrocitinib NCIT:C166985
JAK1 inhibition with abrocitinib has shown symptomatic and severity improvements in case-level NS evidence.
Show evidence (1 reference)
PMID:40159127 SUPPORT Human Clinical
"Following six months of Abrocitinib therapy, the patient exhibited marked improvement in skin rash and overall disease severity."
This supports JAK1 inhibition as a promising targeted option in NS.
Secukinumab and dupilumab combination (investigational/observational)
Action: biologic therapy Ontology label: Immunotherapy NCIT:C15262
Agent: secukinumab NCIT:C152315 dupilumab NCIT:C162455
Combination IL-17A and IL-4/IL-13 blockade has been reported in severe pediatric NS cohorts.
Show evidence (1 reference)
clinicaltrials:NCT07151508 SUPPORT Human Clinical
"In this study, we describe our experience with secukinumab (IL-17A inhibitor) and dupilumab (IL-4/IL-13 inhibitor) treatment of a group of pediatric patients with severe Neterton syndrome."
This supports real-world investigational use of combination biologic therapy in severe pediatric NS.
🔬

Biochemical Markers

2
Total serum IgE (Elevated)
Context: Atopic/inflammatory Netherton syndrome is frequently associated with elevated total IgE, including markedly high baseline values in case-level reports.
Show evidence (3 references)
PMID:40299794 SUPPORT Human Clinical
"The blood tests demonstrated elevated IgE levels."
This directly supports elevated IgE as a biochemical feature in NS.
PMID:40607310 SUPPORT Human Clinical
"Serologically, total his serum IgE levels decreased from 1078 IU/mL to 55.8 IU/mL following dupilumab therapy."
This supports high baseline IgE in NS and demonstrates dynamic change with targeted therapy.
PMID:38406644 SUPPORT Human Clinical
"The patient has atopic diathesis, recurrent skin infections, increased levels of IgE, and delayed physical development."
This supports increased IgE as a recurrent biochemical feature in severe NS.
IL-17/IL-36 inflammatory axis activity (Elevated)
Context: Inflammatory pathway activation is observed in both skin and blood and contributes to persistent erythro-inflammatory disease activity.
Show evidence (2 references)
PMID:40888388 SUPPORT Human Clinical
"NS patients commonly show activation of the inflammatory axis, centered on IL-17 and IL-36, in the skin and blood, and show a psoriasis-like shift to Th17."
This supports IL-17/IL-36 pathway activation as a measurable biochemical-inflammatory signature in NS.
DOI:10.1038/s42003-024-05780-y SUPPORT Model Organism
"Spink5 cKO mice and NS patients share skin barrier and inflammation signatures defined by up-regulation and increased activity of proteases, IL-17, IL-36, and IL-20 family cytokine signaling."
This supports conserved cytokine-axis upregulation across NS patients and mechanistic model systems.
🔀

Differential Diagnoses

5

Conditions with similar clinical presentations that must be differentiated from Netherton syndrome:

Atopic eczema MONDO:0004980
Overlapping Features Severe atopic eczema can clinically overlap with NS, especially early in life with eczematous inflammation and pruritus.
Distinguishing Features
  • Hair shaft abnormalities and inherited ichthyosis features support Netherton syndrome over isolated atopic eczema.
  • Pathogenic SPINK5 variants and LEKTI pathway dysfunction support Netherton syndrome.
Show evidence (2 references)
DOI:10.3390/genes14051080 SUPPORT Human Clinical
"We describe an NS patient, initially misdiagnosed with severe AD, who carried the heterozygous frameshift (null) mutation (NM_006846.4): c.957_960dup combined with homozygous rs2303067 in the SPINK5 gene."
This provides direct evidence of diagnostic confusion between NS and severe atopic dermatitis.
PMID:38601387 SUPPORT Human Clinical
"While eczema was included in our differential diagnoses, the patient's systemic symptoms, including failure to thrive, prompted our team to consider other diagnoses."
This supports practical diagnostic overlap with eczema and the need to broaden differential assessment in severe infantile disease.
Autosomal recessive congenital ichthyosis MONDO:0017265
Overlapping Features NS belongs to inherited ichthyosis disorders and may overlap clinically with other autosomal recessive congenital ichthyosis subtypes.
Distinguishing Features
  • Hair shaft abnormalities and strong atopic/allergic predisposition are characteristic clues favoring Netherton syndrome.
  • SPINK5/LEKTI-associated protease dysregulation provides mechanistic specificity for Netherton syndrome.
Show evidence (1 reference)
PMID:27905021 SUPPORT Human Clinical
"Netherton syndrome (OMIM #256500) is a rare but severe autosomal recessive form of ichthyosis that affects the skin, hair, and immune system."
This supports overlap within ARCI-like ichthyosis presentations while defining NS as a specific syndromic form.
Chanarin-Dorfman syndrome MONDO:0010155
Overlapping Features Chanarin-Dorfman syndrome can overlap with syndromic ichthyosis presentations and requires molecular discrimination from Netherton syndrome.
Distinguishing Features
  • Trichorrhexis invaginata with pathogenic SPINK5 variants supports Netherton syndrome over alternative syndromic ichthyoses.
Show evidence (1 reference)
PMID:40709761 PARTIAL Human Clinical
"Additionally, 4 patients were diagnosed with syndromic ichthyosis, comprising 1 case of Chanarin-Dorfman syndrome and 3 cases of Netherton syndrome."
This supports real-world diagnostic overlap between NS and Chanarin-Dorfman syndrome in inherited ichthyosis cohorts.
Psoriasis MONDO:0005083
Overlapping Features Chronic erythro-scaling inflammatory dermatoses such as psoriasis can mimic Netherton syndrome and delay diagnosis.
Distinguishing Features
  • Hair shaft abnormalities with congenital onset and syndromic ichthyosis features support Netherton syndrome over psoriasis-spectrum diseases.
Show evidence (1 reference)
PMID:38638763 SUPPORT Human Clinical
"We present an unusual case of two incidental diagnoses of NTS in siblings of consanguineous parents, manifesting as erythroderma and other symptoms that were initially diagnosed as pityriasis rubra pilaris and psoriasis in separate visits."
This directly supports real-world diagnostic confusion between NS and psoriasis.
Pityriasis rubra pilaris Not Yet Curated MONDO:0100017
Overlapping Features Pityriasis rubra pilaris can present with erythroderma and scaling that overlap with Netherton syndrome.
Distinguishing Features
  • Hair shaft abnormalities and congenital ichthyosis features support Netherton syndrome over pityriasis rubra pilaris.
Show evidence (1 reference)
PMID:38638763 SUPPORT Human Clinical
"We present an unusual case of two incidental diagnoses of NTS in siblings of consanguineous parents, manifesting as erythroderma and other symptoms that were initially diagnosed as pityriasis rubra pilaris and psoriasis in separate visits."
This directly supports real-world diagnostic confusion between NS and pityriasis rubra pilaris.
📊

Related Datasets

2
Transcriptome profiling of lesional skin from Spink5 conditional knock-out mice geo:GSE224280
GEO transcriptome dataset from lesional skin in a viable Spink5 conditional knock-out Netherton syndrome mouse model.
BULK RNA SEQ
DOI:10.1038/s42003-024-05780-y
Show evidence (1 reference)
GEO:GSE224280 SUPPORT Model Organism
"To characterize this model at the molecular level, we induced Spink5 deletion in young adult mice and collected lesional skin samples for transcriptome analyses."
This supports transcriptomic dataset use for mechanistic profiling of Spink5-deficient skin.
Transcriptome profiling of lymph nodes from Spink5 conditional knock-out mice geo:GSE224409
GEO transcriptome dataset from inguinal lymph nodes in the Spink5 conditional knock-out model to characterize systemic inflammation.
BULK RNA SEQ
DOI:10.1038/s42003-024-05780-y
Show evidence (1 reference)
GEO:GSE224409 SUPPORT Model Organism
"To study the systemic inflammation phenotype of this mouse model at the molecular level, we induced Spink5 deletion in the skin of young adult mice and collected inguinal lymph nodes for transcriptome analyses."
This supports transcriptomic profiling of lymphoid tissue to characterize systemic inflammatory mechanisms in NS models.
🔬

Clinical Trials

3
NCT01545323 PHASE_I UNKNOWN
Phase I ex vivo lentiviral gene therapy trial evaluating autologous epidermal sheets generated from SPINK5-corrected skin stem cells in Netherton syndrome.
Target Phenotypes: Ichthyosis HP:0008064 Erythroderma HP:0001019
Show evidence (2 references)
clinicaltrials:NCT01545323 SUPPORT Human Clinical
"The investigators have been developing a gene therapy approach to treat this disorder."
This supports clinical investigation of a gene therapy approach for Netherton syndrome.
clinicaltrials:NCT01545323 SUPPORT Human Clinical
"In this trial the investigators propose grafting of autologous epidermal sheets generated from genetically modified skin stem cells for the treatment of patients with Netherton Syndrome."
This describes the autologous SPINK5-corrected epidermal sheet intervention evaluated in the study.
NCT04244006 PHASE_II UNKNOWN
Registered as a phase 2/3 pilot randomized placebo-controlled trial of dupilumab for moderate-to-severe Netherton syndrome.
Target Phenotypes: Pruritus HP:0000989 Erythroderma HP:0001019
Show evidence (1 reference)
clinicaltrials:NCT04244006 SUPPORT Human Clinical
"The expected consequences of this study are that a 16-week course of dupilumab will be more effective than placebo for the treatment of moderate to severe NS Dupilumab could therefore improve skin condition and quality of life."
This supports ongoing/registered evaluation of dupilumab for clinically significant NS disease burden.
NCT07151508 NOT_APPLICABLE COMPLETED
Completed observational study describing combination secukinumab and dupilumab use in severe pediatric Netherton syndrome.
Target Phenotypes: Atopic dermatitis HP:0001047
Show evidence (1 reference)
clinicaltrials:NCT07151508 SUPPORT Human Clinical
"In this study, we describe our experience with secukinumab (IL-17A inhibitor) and dupilumab (IL-4/IL-13 inhibitor) treatment of a group of pediatric patients with severe Neterton syndrome."
This supports real-world evidence generation for combination biologic therapy in pediatric NS.
{ }

Source YAML

click to show 
name: Netherton syndrome
creation_date: "2026-02-20T00:00:43Z"
updated_date: "2026-04-22T20:53:03Z"
category: Mendelian
description: >-
  Netherton syndrome is a rare autosomal recessive inherited ichthyosis caused
  by SPINK5 loss-of-function variants, with resulting LEKTI deficiency,
  epidermal barrier dysfunction, chronic skin inflammation, and prominent atopic
  features.
disease_term:
  preferred_term: Netherton syndrome
  term:
    id: MONDO:0009735
    label: Netherton syndrome
classifications:
  harrisons_chapter:
  - classification_value: DERMATOLOGY
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
parents:
- inherited ichthyosis
- genodermatosis
synonyms:
- Comel-Netherton syndrome
- Netherton syndrome
has_subtypes:
- name: Ichthyosiform erythroderma-predominant Netherton syndrome
  description: >-
    Clinical subtype with persistent diffuse erythroderma and ichthyosiform
    scaling.
  evidence:
  - reference: PMID:38634098
    reference_title: "Netherton syndrome-A therapeutic challenge in childhood."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There are two subtypes of the syndrome that differ in clinical presentation and immune profile: ichthyosiform erythroderma and ichthyosis linearis circumflexa."
    explanation: This supports ichthyosiform erythroderma as one recognized clinical subtype of NS.
- name: Ichthyosis linearis circumflexa-predominant Netherton syndrome
  description: >-
    Clinical subtype characterized by migratory polycyclic erythematous plaques
    with characteristic double-edged scale.
  evidence:
  - reference: PMID:38634098
    reference_title: "Netherton syndrome-A therapeutic challenge in childhood."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There are two subtypes of the syndrome that differ in clinical presentation and immune profile: ichthyosiform erythroderma and ichthyosis linearis circumflexa."
    explanation: This supports ichthyosis linearis circumflexa as a second recognized clinical subtype of NS.
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:27905021
    reference_title: "Netherton Syndrome: A Genotype-Phenotype Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Netherton syndrome (OMIM #256500) is a rare but severe autosomal recessive form of ichthyosis that affects the skin, hair, and immune system."
    explanation: This review explicitly states the autosomal recessive inheritance mode for Netherton syndrome.
prevalence:
- population: Live births
  percentage: approximately 1 in 200,000
  notes: >-
    Recent clinical review literature describes Netherton syndrome as an
    ultra-rare disorder with incidence around 1 in 200,000 births.
  evidence:
  - reference: PMID:39546052
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Netherton syndrome (NS) is a rare inborn error of immunity (IEI) with an incidence of approximately 1:200,000 and the phenotypic triad of trichorrhexis invaginate (bamboo hair), congenital ichthyosiform erythroderma, and multiple atopic manifestations."
    explanation: Recent review article provides a direct incidence estimate for Netherton syndrome.
pathophysiology:
- name: SPINK5 loss-of-function variants
  description: >-
    Biallelic pathogenic SPINK5 variants reduce functional SPINK5 output and
    initiate Netherton syndrome pathogenesis.
  genes:
  - preferred_term: SPINK5
    term:
      id: hgnc:15464
      label: SPINK5
  cell_types:
  - preferred_term: keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  locations:
  - preferred_term: skin epidermis
    term:
      id: UBERON:0001003
      label: skin epidermis
  downstream:
  - target: LEKTI protein deficiency
    description: SPINK5 loss of function reduces or abolishes LEKTI protein levels.
  evidence:
  - reference: DOI:10.1038/s42003-024-05780-y
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "AbstractNetherton syndrome (NS) is a rare skin disease caused by loss-of-function mutations in the serine peptidase inhibitor Kazal type 5 (SPINK5) gene."
    explanation: This supports SPINK5 loss of function as the initiating lesion in NS.
  - reference: PMID:40607310
    reference_title: "Successful management of Netherton syndrome using IVIG and dupilumab: A case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Netherton syndrome (NS) is a rare autosomal recessive genodermatosis caused by pathogenic mutations in the serine protease inhibitor Kazal-type 5 (SPINK5) gene, leading to impaired skin barrier function and immune dysregulation."
    explanation: This supports pathogenic SPINK5 variants as the primary molecular driver in human NS.
- name: LEKTI protein deficiency
  description: >-
    Reduced or absent LEKTI removes a key epidermal serine-protease brake in
    skin and hair-bearing epithelium.
  cell_types:
  - preferred_term: keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  locations:
  - preferred_term: skin epidermis
    term:
      id: UBERON:0001003
      label: skin epidermis
  downstream:
  - target: Unchecked epidermal kallikrein protease activity
    description: LEKTI deficiency permits excessive epidermal serine protease activity.
  - target: Hair shaft structural fragility from follicular protease imbalance
    description: LEKTI loss in hair follicles predisposes to bamboo-hair morphology.
  evidence:
  - reference: DOI:10.3390/genes14051080
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Netherton syndrome (NS) is a rare autosomal recessive disorder caused by SPINK5 mutations, resulting in a deficiency in its processed protein LEKTI."
    explanation: This supports LEKTI deficiency as a distinct downstream molecular consequence of SPINK5 defects.
- name: Unchecked epidermal kallikrein protease activity
  description: >-
    Loss of LEKTI control leads to increased epidermal protease activity,
    including KLK-dependent proteolysis in the stratum corneum.
  cell_types:
  - preferred_term: keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  biological_processes:
  - preferred_term: proteolysis
    term:
      id: GO:0006508
      label: proteolysis
  locations:
  - preferred_term: stratum corneum of epidermis
    term:
      id: UBERON:0002027
      label: stratum corneum of epidermis
  downstream:
  - target: Corneodesmosome degradation and accelerated desquamation
    description: Excessive proteolysis promotes premature corneocyte detachment.
  - target: KLK-mediated IL-36 cytokine processing
    description: KLKs proteolytically activate IL-36 family pro-cytokines.
  evidence:
  - reference: DOI:10.1038/s42003-024-05780-y
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Spink5 cKO mice and NS patients share skin barrier and inflammation signatures defined by up-regulation and increased activity of proteases, IL-17, IL-36, and IL-20 family cytokine signaling."
    explanation: This supports increased protease activity as a central intermediary event in NS.
  - reference: DOI:10.1038/s42003-024-05780-y
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "By comparing skin transcriptomes and proteomes, we uncover several putative substrates of tissue kallikrein-related proteases (KLKs), demonstrating that KLKs can proteolytically regulate IL-36 pro-inflammatory cytokines."
    explanation: This directly supports KLK-driven IL-36 cytokine processing.
- name: Corneodesmosome degradation and accelerated desquamation
  description: >-
    Excess serine-protease activity accelerates stratum corneum protein
    breakdown, causing premature shedding and unstable cornified layers.
  biological_processes:
  - preferred_term: proteolysis
    term:
      id: GO:0006508
      label: proteolysis
  - preferred_term: keratinization
    term:
      id: GO:0031424
      label: keratinization
  locations:
  - preferred_term: stratum corneum of epidermis
    term:
      id: UBERON:0002027
      label: stratum corneum of epidermis
  downstream:
  - target: Epidermal barrier breakdown and increased transepidermal water loss
    description: Corneocyte cohesion failure impairs the physical epidermal barrier.
  - target: Ichthyosis
    description: Disordered cornification and scaling manifest clinically as ichthyosis.
  evidence:
  - reference: DOI:10.1038/s42003-024-05780-y
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Spink5 cKO mice and NS patients share skin barrier and inflammation signatures defined by up-regulation and increased activity of proteases, IL-17, IL-36, and IL-20 family cytokine signaling."
    explanation: This supports protease-driven barrier/cornification pathology in NS.
- name: Epidermal barrier breakdown and increased transepidermal water loss
  description: >-
    Defective stratum corneum integrity increases permeability to water, allergens,
    and microbes, establishing chronic barrier failure.
  cell_types:
  - preferred_term: keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  biological_processes:
  - preferred_term: keratinization
    term:
      id: GO:0031424
      label: keratinization
  locations:
  - preferred_term: skin epidermis
    term:
      id: UBERON:0001003
      label: skin epidermis
  downstream:
  - target: Enhanced cutaneous entry of allergens and microbes
    description: Increased permeability raises exposure to environmental antigens and pathogens.
  - target: Recurrent infections
    description: Barrier failure contributes to repeated skin and systemic infections.
  - target: Pruritus
    description: Barrier disruption drives itch through xerosis and neuroimmune activation.
  evidence:
  - reference: DOI:10.1038/s42003-024-05780-y
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Spink5 cKO mice and NS patients share skin barrier and inflammation signatures defined by up-regulation and increased activity of proteases, IL-17, IL-36, and IL-20 family cytokine signaling."
    explanation: This supports barrier dysfunction as a key pathophysiologic hub in NS.
  - reference: PMID:38025195
    reference_title: "Severe Hypernatremia as Presentation of Netherton Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Loss of LEKTI induces severe skin barrier defect."
    explanation: This provides additional human case-level support for severe barrier disruption in NS.
- name: KLK-mediated IL-36 cytokine processing
  description: >-
    KLK proteases cleave IL-36 cytokine precursors, amplifying epidermal
    pro-inflammatory signaling.
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  downstream:
  - target: IL-17/IL-36 inflammatory amplification
    description: IL-36 signaling feeds forward into chronic inflammatory circuits.
  evidence:
  - reference: DOI:10.1038/s42003-024-05780-y
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "By comparing skin transcriptomes and proteomes, we uncover several putative substrates of tissue kallikrein-related proteases (KLKs), demonstrating that KLKs can proteolytically regulate IL-36 pro-inflammatory cytokines."
    explanation: This defines the KLK-to-IL-36 activation step in the NS inflammatory cascade.
  - reference: DOI:10.3390/dermatopathology11030024
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Both cases demonstrated robust expression of IL-36."
    explanation: This supports IL-36 pathway activation in NS patient skin biopsies.
- name: Enhanced cutaneous entry of allergens and microbes
  description: >-
    Persistent barrier failure promotes antigen penetration and microbial exposure,
    increasing both atopic sensitization and infection vulnerability.
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  downstream:
  - target: IL-17/IL-36 inflammatory amplification
    description: Antigen and microbe exposure sustains chronic inflammatory signaling.
  - target: Atopic dermatitis
    description: Cutaneous allergen entry contributes to severe eczematous disease.
  - target: Recurrent infections
    description: Reduced barrier defense promotes repeated infectious episodes.
  evidence:
  - reference: PMID:41126693
    reference_title: "Immunological phenotype and skin modeling of Netherton syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Netherton syndrome (NTS) is a syndromic ichthyosis characterized by scaling, erythroderma, and proneness towards allergies and infections."
    explanation: This supports concurrent allergy-prone and infection-prone consequences of barrier failure.
- name: IL-17/IL-36 inflammatory amplification
  description: >-
    Combined IL-36 and IL-17 pathway activation sustains epidermal inflammation
    and drives persistent erythro-inflammatory and eczematous disease.
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  - preferred_term: interleukin-17-mediated signaling pathway
    term:
      id: GO:0097400
      label: interleukin-17-mediated signaling pathway
  downstream:
  - target: Erythroderma
    description: High inflammatory burden produces diffuse erythema and scaling.
  - target: Atopic dermatitis
    description: Chronic cytokine activation drives eczematous inflammation.
  - target: Pruritus
    description: Cytokine-mediated neuroimmune signaling contributes to severe itch.
  - target: Failure to thrive
    description: Sustained systemic inflammatory burden can impair growth in severe disease.
  evidence:
  - reference: DOI:10.1038/s42003-024-05780-y
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Spink5 cKO mice and NS patients share skin barrier and inflammation signatures defined by up-regulation and increased activity of proteases, IL-17, IL-36, and IL-20 family cytokine signaling."
    explanation: This supports IL-17/IL-36 axis overactivation as a core inflammatory driver in NS.
  - reference: DOI:10.3390/dermatopathology11030024
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Both cases demonstrated robust expression of IL-36."
    explanation: This provides patient-level biopsy support for IL-36-driven inflammation.
- name: Hair shaft structural fragility from follicular protease imbalance
  description: >-
    SPINK5/LEKTI dysfunction in hair-bearing epithelium contributes to defective
    hair-shaft integrity, including trichorrhexis invaginata susceptibility.
  genes:
  - preferred_term: SPINK5
    term:
      id: hgnc:15464
      label: SPINK5
  cell_types:
  - preferred_term: keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  biological_processes:
  - preferred_term: keratinization
    term:
      id: GO:0031424
      label: keratinization
  downstream:
  - target: Hair shaft abnormality
    description: Follicular structural defects manifest as bamboo hair and related shaft anomalies.
  evidence:
  - reference: DOI:10.3390/genes14051080
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is clinically characterized by the triad of congenital ichthyosis, atopic diathesis, and hair shaft abnormalities."
    explanation: This supports hair-shaft defects as a direct disease consequence within the SPINK5/LEKTI mechanism.
phenotypes:
- name: Ichthyosis
  description: Generalized scaling disorder of cornification and barrier function.
  phenotype_term:
    preferred_term: Ichthyosis
    term:
      id: HP:0008064
      label: Ichthyosis
  evidence:
  - reference: DOI:10.3390/genes14051080
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is clinically characterized by the triad of congenital ichthyosis, atopic diathesis, and hair shaft abnormalities."
    explanation: This directly supports ichthyosis as a core clinical manifestation of NS.
- name: Erythroderma
  description: Diffuse inflammatory erythema with scaling involving large skin areas.
  phenotype_term:
    preferred_term: Erythroderma
    term:
      id: HP:0001019
      label: Erythroderma
  evidence:
  - reference: PMID:41126693
    reference_title: "Immunological phenotype and skin modeling of Netherton syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Netherton syndrome (NTS) is a syndromic ichthyosis characterized by scaling, erythroderma, and proneness towards allergies and infections."
    explanation: This explicitly reports erythroderma as a characteristic phenotype in NS.
  - reference: PMID:40299794
    reference_title: "Secukinumab as a Novel Treatment for Chronic Netherton Syndrome in a Young Adult."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical examination showed generalized erythroderma and polycyclic and serpiginous erythematous plaques with double-edged scales at the margins."
    explanation: This case report provides direct clinical evidence for erythroderma in NS.
- name: Hair shaft abnormality
  description: >-
    Hair-shaft defects are characteristic in NS, often including
    trichorrhexis invaginata (bamboo hair).
  phenotype_term:
    preferred_term: Abnormal hairshaft morphology
    term:
      id: HP:0003328
      label: Abnormal hairshaft morphology
  evidence:
  - reference: DOI:10.3390/genes14051080
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is clinically characterized by the triad of congenital ichthyosis, atopic diathesis, and hair shaft abnormalities."
    explanation: This supports hair-shaft abnormalities as a core component of the NS clinical triad.
  - reference: PMID:40299794
    reference_title: "Secukinumab as a Novel Treatment for Chronic Netherton Syndrome in a Young Adult."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Trichoscopy of the scalp revealed a hair shaft abnormality, specifically trichorrhexis invaginata."
    explanation: This provides direct clinical confirmation of characteristic bamboo-hair morphology in NS.
- name: Atopic dermatitis
  description: Eczematous inflammatory skin phenotype overlapping with atopic eczema.
  phenotype_term:
    preferred_term: Atopic dermatitis
    term:
      id: HP:0001047
      label: Atopic dermatitis
  evidence:
  - reference: DOI:10.3390/genes14051080
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We describe an NS patient, initially misdiagnosed with severe AD, who carried the heterozygous frameshift (null) mutation (NM_006846.4): c.957_960dup combined with homozygous rs2303067 in the SPINK5 gene."
    explanation: This supports atopic-dermatitis-like presentations and diagnostic overlap in NS.
  - reference: PMID:40299794
    reference_title: "Secukinumab as a Novel Treatment for Chronic Netherton Syndrome in a Young Adult."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient was previously diagnosed with atopic dermatitis and had been treated with systemic corticosteroids and omalizumab, without improvement."
    explanation: This supports frequent diagnostic overlap and initial misclassification as severe atopic dermatitis.
- name: Pruritus
  description: Chronic itch as a major symptomatic burden in NS.
  phenotype_term:
    preferred_term: Pruritus
    term:
      id: HP:0000989
      label: Pruritus
  evidence:
  - reference: clinicaltrials:NCT04244006
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To date, there are no effective therapy for the management of Netherton Syndrome (NS) Patients use emollients with a limited efficacy on scaling and no efficacy on skin inflammation and pruritus."
    explanation: Trial summary explicitly identifies pruritus as a persistent symptom and treatment target.
  - reference: PMID:40607310
    reference_title: "Successful management of Netherton syndrome using IVIG and dupilumab: A case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He demonstrated substantial clinical benefits, with marked relief from pruritus resulting in better quality of life."
    explanation: This supports that pruritus is a major and treatment-responsive symptomatic burden in NS.
- name: Recurrent infections
  description: Increased susceptibility to recurrent infections associated with barrier dysfunction.
  phenotype_term:
    preferred_term: Recurrent infections
    term:
      id: HP:0002719
      label: Recurrent infections
  evidence:
  - reference: PMID:41126693
    reference_title: "Immunological phenotype and skin modeling of Netherton syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Netherton syndrome (NTS) is a syndromic ichthyosis characterized by scaling, erythroderma, and proneness towards allergies and infections."
    explanation: This supports recurrent infection susceptibility as part of the NS phenotype spectrum.
  - reference: PMID:40607310
    reference_title: "Successful management of Netherton syndrome using IVIG and dupilumab: A case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient was treated with intravenous immunoglobulin due to frequent infections that required multiple hospital admissions."
    explanation: This provides direct case-level evidence for recurrent severe infections in NS.
- name: Failure to thrive
  description: Growth impairment in subsets of patients with severe or specific SPINK5 variant profiles.
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: PMID:39931731
    reference_title: "The role of SPINK5 mutation distribution in phenotypes of Netherton syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We observed that patients with variants or homozygous variants located in the 5' half of the gene were more likely to experience failure to thrive (P < 0.05)."
    explanation: This supports genotype-associated risk of failure to thrive in NS cohorts.
  - reference: PMID:38634098
    reference_title: "Netherton syndrome-A therapeutic challenge in childhood."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We describe an 8-year-old boy with genetically proven NS treated with intravenous immunoglobulin for recurrent skin and systemic infections from infancy, growth retardation, and associated erythroderma."
    explanation: This supports growth retardation/failure-to-thrive manifestations in pediatric NS.
biochemical:
- name: Total serum IgE
  presence: Elevated
  context: >-
    Atopic/inflammatory Netherton syndrome is frequently associated with elevated
    total IgE, including markedly high baseline values in case-level reports.
  evidence:
  - reference: PMID:40299794
    reference_title: "Secukinumab as a Novel Treatment for Chronic Netherton Syndrome in a Young Adult."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The blood tests demonstrated elevated IgE levels."
    explanation: This directly supports elevated IgE as a biochemical feature in NS.
  - reference: PMID:40607310
    reference_title: "Successful management of Netherton syndrome using IVIG and dupilumab: A case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Serologically, total his serum IgE levels decreased from 1078 IU/mL to 55.8 IU/mL following dupilumab therapy."
    explanation: This supports high baseline IgE in NS and demonstrates dynamic change with targeted therapy.
  - reference: PMID:38406644
    reference_title: "Netherton Syndrome with a Novel Likely Pathogenic Variant c.420del (p.Ser141ProfsTer5) in SPINK5 Gene: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient has atopic diathesis, recurrent skin infections, increased levels of IgE, and delayed physical development."
    explanation: This supports increased IgE as a recurrent biochemical feature in severe NS.
- name: IL-17/IL-36 inflammatory axis activity
  presence: Elevated
  context: >-
    Inflammatory pathway activation is observed in both skin and blood and
    contributes to persistent erythro-inflammatory disease activity.
  evidence:
  - reference: PMID:40888388
    reference_title: "Biologics and Small-Molecule Therapies in Netherton Syndrome: A Comprehensive Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "NS patients commonly show activation of the inflammatory axis, centered on IL-17 and IL-36, in the skin and blood, and show a psoriasis-like shift to Th17."
    explanation: This supports IL-17/IL-36 pathway activation as a measurable biochemical-inflammatory signature in NS.
  - reference: DOI:10.1038/s42003-024-05780-y
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Spink5 cKO mice and NS patients share skin barrier and inflammation signatures defined by up-regulation and increased activity of proteases, IL-17, IL-36, and IL-20 family cytokine signaling."
    explanation: This supports conserved cytokine-axis upregulation across NS patients and mechanistic model systems.
genetic:
- name: SPINK5
  gene_term:
    preferred_term: SPINK5
    term:
      id: hgnc:15464
      label: SPINK5
  association: Causative
  notes: >-
    Biallelic SPINK5 loss-of-function is causative, with variant location
    associated with phenotype severity in reported cohorts.
  evidence:
  - reference: DOI:10.3390/genes14051080
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Netherton syndrome (NS) is a rare autosomal recessive disorder caused by SPINK5 mutations, resulting in a deficiency in its processed protein LEKTI."
    explanation: This directly supports SPINK5 as the causal gene and links genotype to LEKTI deficiency.
  - reference: PMID:27905021
    reference_title: "Netherton Syndrome: A Genotype-Phenotype Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The identification of SPINK5, which encodes for the serine protease inhibitor LEKTI, as the gene responsible for Netherton syndrome, enabled the search for causative mutations in Netherton syndrome patients and families."
    explanation: This supports SPINK5 as the established disease gene and highlights genotype-phenotype analysis in affected families.
  - reference: PMID:39931731
    reference_title: "The role of SPINK5 mutation distribution in phenotypes of Netherton syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among 162 patients, we identified 324 allele variants, comprising 75 different mutations."
    explanation: This supports broad allelic heterogeneity and the need for comprehensive SPINK5 variant interpretation.
  - reference: PMID:40159127
    reference_title: "Abrocitinib alleviates the symptoms of Netherton syndrome and is well tolerated."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genetic analysis revealed that the patient harbored compound heterozygous mutations in the SPINK5 gene, including a missense mutation in exon 26 (c.2475G > T, p.Trp825Cys)."
    explanation: This supports ongoing expansion of pathogenic SPINK5 variant classes, including missense alleles.
  - reference: PMID:40969297
    reference_title: "Clinical characteristics of Netherton syndrome and exploration of targeted biologic therapy: two case reports."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Subsequently, genetic testing identified a defective SPINK5 gene, leading to a diagnosis of NS."
    explanation: This provides additional contemporary clinical evidence of SPINK5 defects as the diagnostic molecular basis of NS.
  - reference: PMID:36159989
    reference_title: "A novel mutation in SPINK5 gene underlies a case of atypical Netherton syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We identified a novel frameshift mutation c.2474_2475del (p.Glu825Glyfs*2) in the SPINK5 gene."
    explanation: This adds evidence that novel SPINK5 pathogenic variants continue to be identified in NS.
diagnosis:
- name: SPINK5 molecular genetic testing
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: MAXO:0000127
      label: genetic testing
  description: >-
    Molecular testing of SPINK5 variants is central for confirming diagnosis and
    clarifying overlap with severe atopic dermatitis.
  evidence:
  - reference: DOI:10.3390/genes14051080
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Due to the clinical overlap between NS and AD, we suggest performing SPINK5 genetic testing to search for the SPINK5 (NM_006846.4): c.1258A>G polymorphism (rs2303067) and ensure a correct diagnosis, mainly in doubtful cases."
    explanation: This supports SPINK5 testing as a diagnostic discriminator in overlapping AD-like presentations.
  - reference: PMID:40969297
    reference_title: "Clinical characteristics of Netherton syndrome and exploration of targeted biologic therapy: two case reports."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Subsequently, genetic testing identified a defective SPINK5 gene, leading to a diagnosis of NS."
    explanation: This directly supports SPINK5 molecular confirmation in contemporary NS case diagnosis.
  - reference: PMID:40709761
    reference_title: "The Clinical Spectrum of Rare Inherited Ichthyosis in China: A Review of Thirty-five Cases."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Additionally, 4 patients were diagnosed with syndromic ichthyosis, comprising 1 case of Chanarin-Dorfman syndrome and 3 cases of Netherton syndrome."
    explanation: This supports molecularly informed diagnostic workup in inherited ichthyosis cohorts that include NS cases.
  - reference: PMID:38406644
    reference_title: "Netherton Syndrome with a Novel Likely Pathogenic Variant c.420del (p.Ser141ProfsTer5) in SPINK5 Gene: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genetic testing of SPINK5 gene is key to confirming the diagnosis and starting early treatment."
    explanation: This directly supports SPINK5 testing as a key confirmatory diagnostic strategy.
- name: Skin biopsy with adjunct immunohistochemistry
  diagnosis_term:
    preferred_term: skin biopsy
    term:
      id: MAXO:0000423
      label: biopsy of skin
  description: >-
    Histopathologic evaluation with adjunct IL-36 immunostaining can support
    diagnosis; LEKTI immunostaining alone may be insufficient in some cases.
  evidence:
  - reference: DOI:10.3390/dermatopathology11030024
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "LEKTI IHC was negative in one biopsy, revealing a limitation of this stain in diagnosing NS."
    explanation: This supports using broader biopsy-based immunohistochemical approaches rather than relying only on LEKTI IHC.
  - reference: DOI:10.3390/dermatopathology11030024
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Consequently, immunohistochemistry (IHC) with IL-36 may serve as a potential tool for aiding the histopathological diagnosis of this condition."
    explanation: This supports IL-36 IHC as a potential adjunct in histopathologic diagnosis.
differential_diagnoses:
- name: Atopic eczema
  disease_term:
    preferred_term: atopic eczema
    term:
      id: MONDO:0004980
      label: atopic eczema
  description: >-
    Severe atopic eczema can clinically overlap with NS, especially early in
    life with eczematous inflammation and pruritus.
  distinguishing_features:
  - Hair shaft abnormalities and inherited ichthyosis features support Netherton syndrome over isolated atopic eczema.
  - Pathogenic SPINK5 variants and LEKTI pathway dysfunction support Netherton syndrome.
  evidence:
  - reference: DOI:10.3390/genes14051080
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We describe an NS patient, initially misdiagnosed with severe AD, who carried the heterozygous frameshift (null) mutation (NM_006846.4): c.957_960dup combined with homozygous rs2303067 in the SPINK5 gene."
    explanation: This provides direct evidence of diagnostic confusion between NS and severe atopic dermatitis.
  - reference: PMID:38601387
    reference_title: "Interprofessional Collaboration: Differentiating Netherton Syndrome and Atopic Dermatitis in an African American Infant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "While eczema was included in our differential diagnoses, the patient's systemic symptoms, including failure to thrive, prompted our team to consider other diagnoses."
    explanation: This supports practical diagnostic overlap with eczema and the need to broaden differential assessment in severe infantile disease.
- name: Autosomal recessive congenital ichthyosis
  disease_term:
    preferred_term: autosomal recessive congenital ichthyosis
    term:
      id: MONDO:0017265
      label: autosomal recessive congenital ichthyosis
  description: >-
    NS belongs to inherited ichthyosis disorders and may overlap clinically with
    other autosomal recessive congenital ichthyosis subtypes.
  distinguishing_features:
  - Hair shaft abnormalities and strong atopic/allergic predisposition are characteristic clues favoring Netherton syndrome.
  - SPINK5/LEKTI-associated protease dysregulation provides mechanistic specificity for Netherton syndrome.
  evidence:
  - reference: PMID:27905021
    reference_title: "Netherton Syndrome: A Genotype-Phenotype Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Netherton syndrome (OMIM #256500) is a rare but severe autosomal recessive form of ichthyosis that affects the skin, hair, and immune system."
    explanation: This supports overlap within ARCI-like ichthyosis presentations while defining NS as a specific syndromic form.
- name: Chanarin-Dorfman syndrome
  disease_term:
    preferred_term: Dorfman-Chanarin disease
    term:
      id: MONDO:0010155
      label: Dorfman-Chanarin disease
  description: >-
    Chanarin-Dorfman syndrome can overlap with syndromic ichthyosis
    presentations and requires molecular discrimination from Netherton syndrome.
  distinguishing_features:
  - Trichorrhexis invaginata with pathogenic SPINK5 variants supports Netherton syndrome over alternative syndromic ichthyoses.
  evidence:
  - reference: PMID:40709761
    reference_title: "The Clinical Spectrum of Rare Inherited Ichthyosis in China: A Review of Thirty-five Cases."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Additionally, 4 patients were diagnosed with syndromic ichthyosis, comprising 1 case of Chanarin-Dorfman syndrome and 3 cases of Netherton syndrome."
    explanation: This supports real-world diagnostic overlap between NS and Chanarin-Dorfman syndrome in inherited ichthyosis cohorts.
- name: Psoriasis
  disease_term:
    preferred_term: psoriasis
    term:
      id: MONDO:0005083
      label: psoriasis
  description: >-
    Chronic erythro-scaling inflammatory dermatoses such as psoriasis can mimic
    Netherton syndrome and delay diagnosis.
  distinguishing_features:
  - Hair shaft abnormalities with congenital onset and syndromic ichthyosis features support Netherton syndrome over psoriasis-spectrum diseases.
  evidence:
  - reference: PMID:38638763
    reference_title: "Two Incidental Sibling Diagnoses of Netherton Syndrome in Separate Visits: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We present an unusual case of two incidental diagnoses of NTS in siblings of consanguineous parents, manifesting as erythroderma and other symptoms that were initially diagnosed as pityriasis rubra pilaris and psoriasis in separate visits."
    explanation: This directly supports real-world diagnostic confusion between NS and psoriasis.
- name: Pityriasis rubra pilaris
  disease_term:
    preferred_term: pityriasis rubra pilaris
    term:
      id: MONDO:0100017
      label: pityriasis rubra pilaris
  description: >-
    Pityriasis rubra pilaris can present with erythroderma and scaling that
    overlap with Netherton syndrome.
  distinguishing_features:
  - Hair shaft abnormalities and congenital ichthyosis features support Netherton syndrome over pityriasis rubra pilaris.
  evidence:
  - reference: PMID:38638763
    reference_title: "Two Incidental Sibling Diagnoses of Netherton Syndrome in Separate Visits: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We present an unusual case of two incidental diagnoses of NTS in siblings of consanguineous parents, manifesting as erythroderma and other symptoms that were initially diagnosed as pityriasis rubra pilaris and psoriasis in separate visits."
    explanation: This directly supports real-world diagnostic confusion between NS and pityriasis rubra pilaris.
treatments:
- name: Supportive topical skin care
  description: >-
    Emollients and topical anti-inflammatory therapy remain baseline management
    for scaling and eczematous inflammation, though control is often incomplete.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: clinicaltrials:NCT04244006
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To date, there are no effective therapy for the management of Netherton Syndrome (NS) Patients use emollients with a limited efficacy on scaling and no efficacy on skin inflammation and pruritus."
    explanation: This trial summary supports current reliance on topical supportive care and its limitations.
- name: Ex vivo SPINK5 gene-corrected epidermal sheet grafting (investigational)
  description: >-
    Phase I ex vivo lentiviral gene therapy strategy using autologous epidermal
    sheets generated from genetically modified skin stem cells to restore LEKTI
    in Netherton syndrome.
  treatment_term:
    preferred_term: gene therapy
    term:
      id: MAXO:0001001
      label: gene therapy
  evidence:
  - reference: clinicaltrials:NCT01545323
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The investigators have used a disabled virus (vector) to carry a functional copy of the SPINK5 gene into skin stem cells."
    explanation: This supports an ex vivo lentiviral SPINK5 gene-correction strategy in NS.
  - reference: clinicaltrials:NCT01545323
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this trial the investigators propose grafting of autologous epidermal sheets generated from genetically modified skin stem cells for the treatment of patients with Netherton Syndrome."
    explanation: This supports autologous epidermal sheet grafting from genetically corrected skin stem cells as the investigational treatment approach.
- name: Cytokine-targeted systemic pharmacotherapy
  description: >-
    Biologics and JAK inhibitors are emerging options in severe disease,
    targeting IL-4/IL-13, IL-17, IL-36, and JAK pathways.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: dupilumab
      term:
        id: NCIT:C162455
        label: Dupilumab
    - preferred_term: secukinumab
      term:
        id: NCIT:C152315
        label: Secukinumab
    - preferred_term: abrocitinib
      term:
        id: NCIT:C166985
        label: Abrocitinib
  evidence:
  - reference: PMID:40888388
    reference_title: "Biologics and Small-Molecule Therapies in Netherton Syndrome: A Comprehensive Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This review provides a comprehensive overview of the current clinical landscape and future directions of biologics (e.g., dupilumab, secukinumab, ustekinumab) and small-molecule therapies (e.g., JAK inhibitors such as tofacitinib, baricitinib, and upadacitinib) in the treatment of NS."
    explanation: This supports use of cytokine-targeted and JAK-pathway therapies in severe NS.
  - reference: PMID:40888388
    reference_title: "Biologics and Small-Molecule Therapies in Netherton Syndrome: A Comprehensive Review."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Though evidence remains limited to case reports and small series, preliminary data suggest that cytokine-targeted interventions-particularly those inhibiting IL-4, IL-13, IL-17, IL-36, and JAK pathways-may offer tangible clinical benefits."
    explanation: This supports potential efficacy while acknowledging current evidence limits.
  - reference: PMID:40969297
    reference_title: "Clinical characteristics of Netherton syndrome and exploration of targeted biologic therapy: two case reports."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Both patients had swift and enduring enhancement of skin lesions during the follow-up period."
    explanation: This case series adds contemporary human evidence that biologic pathway targeting can improve NS skin disease.
- name: Immunoglobulin and biologic systemic therapy
  description: >-
    Systematic review data indicate skin improvement in many reported cases with
    immunoglobulins and biologics.
  treatment_term:
    preferred_term: intravenous immunoglobulin therapy
    term:
      id: MAXO:0001480
      label: immunoglobulin infusion therapy
    therapeutic_agent:
    - preferred_term: dupilumab
      term:
        id: NCIT:C162455
        label: Dupilumab
    - preferred_term: secukinumab
      term:
        id: NCIT:C152315
        label: Secukinumab
  evidence:
  - reference: PMID:35464459
    reference_title: "Outcomes of Systemic Treatment in Children and Adults With Netherton Syndrome: A Systematic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Immunoglobulins (13/15 cases) and biologicals (18/21 cases) showed improvement of the skin."
    explanation: This supports observed skin benefit in aggregated case-based treatment evidence.
  - reference: PMID:38634098
    reference_title: "Netherton syndrome-A therapeutic challenge in childhood."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Under this therapy, his skin status, infectious exacerbations, and quality of life all improved."
    explanation: This provides additional pediatric case-level support for IVIG-centered systemic therapy.
- name: Intravenous immunoglobulin (IVIG) for infection-prone pediatric NS
  description: >-
    High-dose IVIG has been used in children with recurrent skin/systemic
    infections and severe inflammatory skin disease, with reported improvement in
    skin status and infectious exacerbations.
  treatment_term:
    preferred_term: intravenous immunoglobulin therapy
    term:
      id: MAXO:0001480
      label: immunoglobulin infusion therapy
  evidence:
  - reference: PMID:38634098
    reference_title: "Netherton syndrome-A therapeutic challenge in childhood."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "KEY CLINICAL MESSAGE: High-dose intravenous immunoglobulin exhibits great potential in the treatment of Netherton syndrome."
    explanation: This explicitly supports IVIG as a promising strategy in pediatric NS.
  - reference: PMID:40607310
    reference_title: "Successful management of Netherton syndrome using IVIG and dupilumab: A case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient was treated with intravenous immunoglobulin due to frequent infections that required multiple hospital admissions."
    explanation: This supports IVIG use in infection-prone NS with severe recurrent admissions.
- name: Dupilumab (IL-4/IL-13 pathway inhibition)
  description: >-
    Dupilumab has shown improvement in pruritus and inflammatory skin disease in
    pediatric and mixed-age NS case reports/series.
  treatment_term:
    preferred_term: biologic therapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
    therapeutic_agent:
    - preferred_term: dupilumab
      term:
        id: NCIT:C162455
        label: Dupilumab
  evidence:
  - reference: PMID:40607310
    reference_title: "Successful management of Netherton syndrome using IVIG and dupilumab: A case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "When he was 6 years old, dupilumab was added to reduce skin inflammation and improve skin barrier function before food reintroduction."
    explanation: This supports dupilumab targeting inflammatory and barrier manifestations in pediatric NS.
  - reference: PMID:40969297
    reference_title: "Clinical characteristics of Netherton syndrome and exploration of targeted biologic therapy: two case reports."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The child received treatment with dupilumab, while the 19-year-old woman alternated between using dupilumab and secukinumab."
    explanation: This supports real-world use of dupilumab across pediatric and young-adult NS cases.
  - reference: PMID:35327681
    reference_title: "Dupilumab Improves Pruritus in Netherton Syndrome: A Case Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Since treatment with various antihistamines were not effective, we administered dupilumab and found that it was effective in immediate elimination of pruritus and gradual reduction of the rash."
    explanation: This adds additional case-level evidence for dupilumab benefit on pruritus and inflammatory skin burden.
- name: Secukinumab (IL-17 pathway inhibition)
  description: >-
    IL-17A blockade with secukinumab has shown clinical improvement in refractory
    NS in case-level evidence.
  treatment_term:
    preferred_term: biologic therapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
    therapeutic_agent:
    - preferred_term: secukinumab
      term:
        id: NCIT:C152315
        label: Secukinumab
  evidence:
  - reference: PMID:40299794
    reference_title: "Secukinumab as a Novel Treatment for Chronic Netherton Syndrome in a Young Adult."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "After 2 injections, the patient's condition markedly improved and the effect after the last injection was maintained for 4-5 months."
    explanation: This supports clinically meaningful short-term and sustained response to secukinumab in refractory NS.
  - reference: PMID:40969297
    reference_title: "Clinical characteristics of Netherton syndrome and exploration of targeted biologic therapy: two case reports."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The child received treatment with dupilumab, while the 19-year-old woman alternated between using dupilumab and secukinumab."
    explanation: This supports secukinumab use as part of targeted biologic treatment strategies in NS.
- name: Abrocitinib (JAK1 inhibitor)
  description: >-
    JAK1 inhibition with abrocitinib has shown symptomatic and severity
    improvements in case-level NS evidence.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: abrocitinib
      term:
        id: NCIT:C166985
        label: Abrocitinib
  evidence:
  - reference: PMID:40159127
    reference_title: "Abrocitinib alleviates the symptoms of Netherton syndrome and is well tolerated."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Following six months of Abrocitinib therapy, the patient exhibited marked improvement in skin rash and overall disease severity."
    explanation: This supports JAK1 inhibition as a promising targeted option in NS.
- name: Secukinumab and dupilumab combination (investigational/observational)
  description: >-
    Combination IL-17A and IL-4/IL-13 blockade has been reported in severe
    pediatric NS cohorts.
  treatment_term:
    preferred_term: biologic therapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
    therapeutic_agent:
    - preferred_term: secukinumab
      term:
        id: NCIT:C152315
        label: Secukinumab
    - preferred_term: dupilumab
      term:
        id: NCIT:C162455
        label: Dupilumab
  evidence:
  - reference: clinicaltrials:NCT07151508
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this study, we describe our experience with secukinumab (IL-17A inhibitor) and dupilumab (IL-4/IL-13 inhibitor) treatment of a group of pediatric patients with severe Neterton syndrome."
    explanation: This supports real-world investigational use of combination biologic therapy in severe pediatric NS.
clinical_trials:
- name: NCT01545323
  phase: PHASE_I
  status: UNKNOWN
  description: >-
    Phase I ex vivo lentiviral gene therapy trial evaluating autologous
    epidermal sheets generated from SPINK5-corrected skin stem cells in
    Netherton syndrome.
  target_phenotypes:
  - preferred_term: Ichthyosis
    term:
      id: HP:0008064
      label: Ichthyosis
  - preferred_term: Erythroderma
    term:
      id: HP:0001019
      label: Erythroderma
  evidence:
  - reference: clinicaltrials:NCT01545323
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The investigators have been developing a gene therapy approach to treat this disorder."
    explanation: This supports clinical investigation of a gene therapy approach for Netherton syndrome.
  - reference: clinicaltrials:NCT01545323
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this trial the investigators propose grafting of autologous epidermal sheets generated from genetically modified skin stem cells for the treatment of patients with Netherton Syndrome."
    explanation: This describes the autologous SPINK5-corrected epidermal sheet intervention evaluated in the study.
- name: NCT04244006
  phase: PHASE_II
  status: UNKNOWN
  description: >-
    Registered as a phase 2/3 pilot randomized placebo-controlled trial of
    dupilumab for moderate-to-severe Netherton syndrome.
  target_phenotypes:
  - preferred_term: Pruritus
    term:
      id: HP:0000989
      label: Pruritus
  - preferred_term: Erythroderma
    term:
      id: HP:0001019
      label: Erythroderma
  evidence:
  - reference: clinicaltrials:NCT04244006
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The expected consequences of this study are that a 16-week course of dupilumab will be more effective than placebo for the treatment of moderate to severe NS Dupilumab could therefore improve skin condition and quality of life."
    explanation: This supports ongoing/registered evaluation of dupilumab for clinically significant NS disease burden.
- name: NCT07151508
  phase: NOT_APPLICABLE
  status: COMPLETED
  description: >-
    Completed observational study describing combination secukinumab and
    dupilumab use in severe pediatric Netherton syndrome.
  target_phenotypes:
  - preferred_term: Atopic dermatitis
    term:
      id: HP:0001047
      label: Atopic dermatitis
  evidence:
  - reference: clinicaltrials:NCT07151508
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this study, we describe our experience with secukinumab (IL-17A inhibitor) and dupilumab (IL-4/IL-13 inhibitor) treatment of a group of pediatric patients with severe Neterton syndrome."
    explanation: This supports real-world evidence generation for combination biologic therapy in pediatric NS.
datasets:
- accession: geo:GSE224280
  title: Transcriptome profiling of lesional skin from Spink5 conditional knock-out mice
  description: >-
    GEO transcriptome dataset from lesional skin in a viable Spink5 conditional
    knock-out Netherton syndrome mouse model.
  data_type: BULK_RNA_SEQ
  publication: DOI:10.1038/s42003-024-05780-y
  evidence:
  - reference: GEO:GSE224280
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "To characterize this model at the molecular level, we induced Spink5 deletion in young adult mice and collected lesional skin samples for transcriptome analyses."
    explanation: This supports transcriptomic dataset use for mechanistic profiling of Spink5-deficient skin.
- accession: geo:GSE224409
  title: Transcriptome profiling of lymph nodes from Spink5 conditional knock-out mice
  description: >-
    GEO transcriptome dataset from inguinal lymph nodes in the Spink5
    conditional knock-out model to characterize systemic inflammation.
  data_type: BULK_RNA_SEQ
  publication: DOI:10.1038/s42003-024-05780-y
  evidence:
  - reference: GEO:GSE224409
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "To study the systemic inflammation phenotype of this mouse model at the molecular level, we induced Spink5 deletion in the skin of young adult mice and collected inguinal lymph nodes for transcriptome analyses."
    explanation: This supports transcriptomic profiling of lymphoid tissue to characterize systemic inflammatory mechanisms in NS models.
📚

References & Deep Research

Deep Research

1
Falcon ▸
Disease Pathophysiology Research Template
Edison Scientific Literature 19 citations 2026-02-19T19:25:49.198189

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

  • Disease Name: Netherton syndrome
  • MONDO ID: (if available)
  • Category: Mendelian

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Netherton syndrome. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

  • What are the primary pathophysiological mechanisms?
  • What molecular pathways are dysregulated?
  • What cellular processes are affected?

2. Key Molecular Players

  • Genes/Proteins: Which genes are causally involved or implicated?
  • Chemical Entities: What metabolites, drugs, or small molecules are relevant?
  • Cell Types: Which cell types are primarily affected?
  • Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

  • What biological processes (GO terms) are disrupted?
  • Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

  • Where in the cell do key processes occur?
  • Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

  • What is the sequence of events from initial trigger to clinical manifestation?
  • Are there distinct stages or phases?

6. Phenotypic Manifestations

  • What are the key clinical phenotypes?
  • How do they relate to the underlying mechanisms?

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Title: Pathophysiology of Netherton Syndrome (NS): a 2023–2024–focused molecular/cellular research report

  1. Disease identifiers and current definition

Disease: Netherton syndrome (NS) is a rare, severe Mendelian disorder of epidermal barrier function and immune/allergic dysregulation caused by loss-of-function variants in SPINK5, encoding the serine protease inhibitor LEKTI. In Open Targets, NS is mapped to MONDO_0009735 and is strongly associated with SPINK5. (moltrasio2023nethertonsyndromecaused pages 1-2)

Identifiers - MONDO: MONDO_0009735 (Open Targets disease page; accessed via Open Targets API in this run). - OMIM: #256500 (moltrasio2023nethertonsyndromecaused pages 1-2)

Epidemiology (recently reiterated) - Petrova et al. (2024) states NS affects ~1:200,000 persons worldwide. (petrova2024comparativeanalysesof pages 1-2) - Moltrasio et al. (2023) summarizes incidence estimates around ~1:100,000–1:200,000 and notes prevalence estimates. (moltrasio2023nethertonsyndromecaused pages 1-2)

  1. Core pathophysiology: key concepts and current understanding

2.1 Primary molecular defect: SPINK5/LEKTI deficiency → uncontrolled epidermal proteolysis

Core concept - NS is fundamentally a “protease-inhibitor” disease: SPINK5 loss leads to functional deficiency of LEKTI, which normally restrains epidermal serine protease activity.

Mechanistic chain (barrier and inflammation) - Petrova et al. (2024) describes LEKTI as expressed in differentiated epidermis and normally inhibiting multiple serine proteases including KLK5, KLK6, KLK7, KLK13, and KLK14 (as well as cathepsin G and caspase-14). LEKTI deficiency results in “unrestrained proteolytic activity.” (petrova2024comparativeanalysesof pages 1-2) - Moltrasio et al. (2023) describes that SPINK5 mutations leading to LEKTI dysfunction produce “persistent activation of skin kallikreins (KLK) and increased premature degradation of desmosomal and corneodesmosomal cadherins.” (moltrasio2023nethertonsyndromecaused pages 1-2)

2.2 Barrier breakdown mechanisms

(1) Corneodesmosome/desmosome cleavage → premature detachment of stratum corneum - Petrova et al. (2024) links uncontrolled epidermal proteases to “proteolytic degradation of (corneo)desmosomal cadherins and stratum corneum lipid-processing enzymes,” producing barrier defects and premature detachment. (petrova2024comparativeanalysesof pages 1-2) - Moltrasio et al. (2023) highlights premature degradation of desmosomal/corneodesmosomal cadherins and impaired keratinization/cornification. (moltrasio2023nethertonsyndromecaused pages 1-2, moltrasio2023nethertonsyndromecaused pages 5-7)

(2) Defective stratum corneum processing and keratinization - Petrova et al. (2024) reports enrichment of GO terms related to keratinization and protease activity in NS/Spink5-cKO shared signatures and emphasizes that focusing on “protease activity” improves correlation to human NS, “indicating the key role of protease activity in NS pathogenesis.” (petrova2024comparativeanalysesof pages 6-7)

2.3 Protease-activated inflammatory signaling: PAR2 axis and epithelial “alarmins”

PAR2 as a bridge from proteolysis to inflammation - Petrova et al. (2024) states that unrestrained protease activity promotes inflammation via “proteolytic activation of PAR-2 signaling” and by proteolytic processing of complement C3 and IL-1B. (petrova2024comparativeanalysesof pages 1-2) - Moltrasio et al. (2023) provides a canonical quote connecting kallikrein hyperactivity to Th2 skewing: “unregulated KLK5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in LEKTI-deficient epidermis.” (moltrasio2023nethertonsyndromecaused pages 5-7)

Downstream mediators and epithelial activation - Moltrasio et al. (2023) explicitly lists downstream mediators induced in this cascade, including “thymic stromal lymphopoietin (TSLP), tumor necrosis factor (TNF)-α, interleukin (IL)-8, and intercellular adhesion molecule 1 (ICAM-1).” (moltrasio2023nethertonsyndromecaused pages 1-2)

2.4 Immune dysregulation: mixed Th2 + Th17/IL-17/IL-36 programs

Th17/IL-17/IL-36 signature (psoriasis-like overlap) - Petrova et al. (2024) reports shared NS patient and Spink5 conditional KO signatures with “up-regulation and increased activity of proteases, IL-17, IL-36, and IL-20 family cytokine signaling” and identifies a conserved “KLK/IL-36 signaling axis.” (petrova2024comparativeanalysesof pages 1-2) - Petrova et al. (2024) transcriptomic heatmaps include IL17A, IL17C, IL17F, IL36A, IL36G, IL36RN, IL22, IL23A, IL1A and IL1B as part of the immune/inflammatory response signature. (petrova2024comparativeanalysesof pages 6-7) - Pawlowski et al. (2024) reports that “Both cases demonstrated robust expression of IL-36,” supporting that NS is “at least in part, driven by Th17 inflammation.” (pawlowski2024interleukin36ishighly pages 1-2, pawlowski2024interleukin36ishighly pages 5-6)

Th2/atopic features - Moltrasio et al. (2023) links LEKTI dysfunction with atopy and elevated IgE, and notes potential mechanisms via altered thymic T-cell maturation affecting Th2 responsiveness. (moltrasio2023nethertonsyndromecaused pages 2-5)

  1. Key molecular players (genes/proteins; chemicals; cells; tissues)

3.1 Genes and proteins (HGNC symbols)

Causal gene - SPINK5 (HGNC: serine peptidase inhibitor Kazal type 5); protein: LEKTI. (moltrasio2023nethertonsyndromecaused pages 1-2, petrova2024comparativeanalysesof pages 1-2)

Protease cascade / enzymes - Kallikreins inhibited by LEKTI: KLK5, KLK6, KLK7, KLK13, KLK14. (petrova2024comparativeanalysesof pages 1-2) - Additional proteases referenced: Cathepsin G, Caspase-14. (petrova2024comparativeanalysesof pages 1-2)

Barrier structural targets (proteolysis substrates) - Desmosomal/corneodesmosomal cadherins (e.g., desmoglein 1 [DSG1], desmocollin 1 [DSC1]) are reduced/cleaved in the setting of protease hyperactivity, impairing barrier adhesion. (moltrasio2023nethertonsyndromecaused pages 5-7, kline2024staphylococcusaureusproteases pages 1-2)

Inflammatory and cytokine pathway genes - IL17A/IL17C/IL17F; IL36A/IL36G/IL36RN; IL22; IL23A; IL1A/IL1B. (petrova2024comparativeanalysesof pages 6-7) - TSLP, TNF, IL8 (CXCL8), ICAM1. (moltrasio2023nethertonsyndromecaused pages 1-2)

Receptors / innate signaling - PAR-2 (protease-activated receptor 2) is directly implicated as protease-activated inflammatory signaling node. (petrova2024comparativeanalysesof pages 1-2, moltrasio2023nethertonsyndromecaused pages 5-7)

3.2 Chemical entities (CHEBI-level concepts)

No specific metabolites were directly quantified in the retrieved NS-specific mechanistic primary sources. Relevant therapeutic chemical entities appearing in current implementations include biologics (dupilumab, secukinumab) and small-molecule JAK inhibitors (baricitinib, upadacitinib) noted in expert reviews; additionally, antibiotics are used for infection control. (morizane2025biologicsandsmall‐molecule pages 8-9, NCT07151508 chunk 1, moltrasio2023nethertonsyndromecaused pages 2-5)

3.3 Cell types (CL-level concepts)

Primary affected cell type - Keratinocytes (epidermal keratinocytes) are the key cell type where LEKTI is processed and where protease/alarmin/cytokine cascades are initiated. (pawlowski2024interleukin36ishighly pages 6-8)

Immune cell involvement - Neutrophils are implicated in systemic inflammation of Spink5 cKO mice and are consistent with Th17/IL-17/IL-36-driven neutrophil recruitment (via CXCL8/CCL20 pathways described in Pawlowski et al.). (petrova2024comparativeanalysesof pages 1-2, pawlowski2024interleukin36ishighly pages 2-5) - CD4+ lymphocytes are explicitly measured for IL-17A levels in the observational combination-biologic cohort. (NCT07151508 chunk 1)

3.4 Anatomical locations/tissues (UBERON-level concepts)

Skin and epidermal layers - Epidermis and stratum corneum; LEKTI secretion occurs at the granular–cornified interface; superficial stratum granulosum is referenced. (petrova2024comparativeanalysesof pages 1-2, pawlowski2024interleukin36ishighly pages 6-8)

Hair - Hair shaft abnormalities (e.g., trichorrhexis invaginata) are part of the disease triad and are explicitly linked to NS definition in Moltrasio et al. (2023). (moltrasio2023nethertonsyndromecaused pages 5-7)

Thymus / immune organs - Petrova et al. (2024) notes LEKTI expression in thymic medullary epithelium and reports systemic inflammation in Spink5 cKO mice correlating with severity and associated with thymic atrophy and lymphoid organ enlargement. (petrova2024comparativeanalysesof pages 1-2)

Other epithelia - Moltrasio et al. (2023) mentions mucous epithelia, trachea and sinonasal epithelium as sites where LEKTI may be relevant. (moltrasio2023nethertonsyndromecaused pages 1-2)

  1. Biological processes disrupted (GO-style terms)

Directly supported processes (examples for GO annotation) - Proteolysis / protease activity: enriched and central to NS pathogenesis in shared transcriptomic signatures. (petrova2024comparativeanalysesof pages 6-7) - Negative regulation of peptidase activity: enriched among upregulated genes (reflecting compensatory protease-inhibitor induction such as SLPI, SPINK7, CSTA, SERPINB3/4). (petrova2024comparativeanalysesof pages 6-7) - Keratinization / cornification: enriched GO terms and described clinically as abnormal cornification. (petrova2024comparativeanalysesof pages 6-7, moltrasio2023nethertonsyndromecaused pages 1-2) - Immune and inflammatory response: shared transcriptomic signature with IL-17/IL-36/IL-1/IL-23 genes. (petrova2024comparativeanalysesof pages 6-7) - Desquamation (conceptually): LEKTI fragments “control desquamation through a pH-dependent interaction.” (petrova2024comparativeanalysesof pages 22-22)

  1. Cellular components: where key processes occur

  2. Lamellar granules: LEKTI is localized to lamellar granules and secreted in superficial stratum granulosum, supporting an epidermal secretory pathway/vesicular compartment for protease inhibition. (pawlowski2024interleukin36ishighly pages 6-8, petrova2024comparativeanalysesof pages 22-22)

  3. Extracellular space / stratum corneum interface: major protease–inhibitor interactions occur at/near the granular–cornified interface, affecting corneodesmosomes and lipid-processing enzymes. (petrova2024comparativeanalysesof pages 1-2)

  4. Disease progression model (molecular → cellular → clinical)

Stage 0: Genetic cause and early-life onset - Loss-of-function SPINK5 variants reduce functional LEKTI. (moltrasio2023nethertonsyndromecaused pages 1-2, petrova2024comparativeanalysesof pages 1-2)

Stage 1: Protease dysregulation and barrier breakdown - Uncontrolled KLK activity drives cleavage of corneodesmosomal cadherins and lipid-processing enzymes, causing premature detachment of stratum corneum and impaired barrier function. (petrova2024comparativeanalysesof pages 1-2)

Stage 2: Protease-triggered innate signaling and epithelial cytokine release - Proteolytic activation of PAR-2 signaling and processing of IL-1B/complement contributes to inflammation; KLK5→PAR2→TSLP links protease dysregulation to atopic inflammation. (petrova2024comparativeanalysesof pages 1-2, moltrasio2023nethertonsyndromecaused pages 5-7)

Stage 3: Adaptive immune skewing and chronic inflammation - NS skin shows overlapping Th2 and Th17 programs; Th17/IL-17/IL-36 signature is supported by multi-omics (Petrova 2024) and IL-36 IHC (Pawlowski 2024). (petrova2024comparativeanalysesof pages 1-2, pawlowski2024interleukin36ishighly pages 1-2)

Stage 4: Systemic consequences (subset / modeled) - In Spink5 cKO mice, systemic inflammation correlates with severity, is marked by neutrophils and IL-17/IL-22 signaling, and associates with thymic atrophy and lymphoid organ enlargement, independent of bacterial infection. (petrova2024comparativeanalysesof pages 1-2)

  1. Phenotypic manifestations (HP-style concepts) and mechanistic links

Core clinical triad - Congenital ichthyosis / erythroderma and scaling: driven by barrier failure from protease-mediated corneodesmosome degradation and altered keratinization. (petrova2024comparativeanalysesof pages 1-2, moltrasio2023nethertonsyndromecaused pages 5-7) - Atopic diathesis / hyper-IgE: linked to TSLP induction and Th2 skewing; Moltrasio case reports IgE 200–1000 IU/mL (normal <120), and Pawlowski reports a case IgE 5251 kU/L. (moltrasio2023nethertonsyndromecaused pages 2-5, pawlowski2024interleukin36ishighly pages 1-2) - Hair shaft defect (trichorrhexis invaginata): hallmark phenotype documented in Moltrasio. (moltrasio2023nethertonsyndromecaused pages 5-7)

Histopathology (mechanistic correlates) - Pawlowski describes psoriasiform epidermal hyperplasia/parakeratosis and diminished granular layer, consistent with Th17/IL-36 and hyperproliferative programs. (pawlowski2024interleukin36ishighly pages 1-2)

  1. Recent developments and latest research (prioritizing 2023–2024)

8.1 Conserved multi-omics disease framework and KLK/IL-36 axis (2024)

  • Petrova et al. (2024, Communications Biology; published Feb 2024; https://doi.org/10.1038/s42003-024-05780-y) created a viable Spink5 conditional knockout model enabling disease-progression study and found common human/mouse signatures featuring protease upregulation and IL-17/IL-36/IL-20 family cytokine pathways; they propose a “KLK/IL-36 signaling axis.” (petrova2024comparativeanalysesof pages 1-2)

8.2 Diagnostic adjunct: IL-36 immunostaining (2024)

  • Pawlowski et al. (2024, Dermatopathology; Aug 2024; https://doi.org/10.3390/dermatopathology11030024) observed that “Both cases demonstrated robust expression of IL-36,” suggesting IL-36 IHC as an ancillary diagnostic tool when LEKTI IHC is inconsistent. (pawlowski2024interleukin36ishighly pages 1-2)

8.3 Quantitative/omics thresholds for shared pathways (2024)

  • Petrova et al. (2024) describes differential expression thresholds (adjusted P<0.05; |log2FC|>1) and shows enrichment of keratinization and protease activity GO terms, supporting protease activity as a central mechanism and a rational therapeutic target class (protease inhibitors, cytokine blockade). (petrova2024comparativeanalysesof pages 6-7)

8.4 Visual mechanistic synthesis (2024)

  • Petrova et al. (2024) includes a schematic summary of up/downregulated pathways in the Spink5 cKO model (protease activity and immune/inflammatory responses including IL-17/IL-22). (petrova2024comparativeanalysesof media 61a4f2db)

  • Current applications and real-world implementation (therapies)

9.1 Standard-of-care symptomatic management - Moltrasio et al. (2023) notes that “no fully satisfactory therapies exist,” and describes current real-world management including emollients and topical corticosteroids, antibacterial agents, and in severe cases intravenous immunoglobulin or biologics such as dupilumab; experimental approaches include bacteriophage- and gene-based therapies. (moltrasio2023nethertonsyndromecaused pages 2-5)

9.2 Targeted immune modulation (off-label and early clinical trials)

Dupilumab (IL-4Rα; IL-4/IL-13 axis) - Randomized controlled trial in progress/registered: NCT04244006 (University Hospital, Toulouse; start date 2020-07-23; primary completion estimated 2024-06-01). Design: Phase 2/3 pilot RCT, double-blind placebo-controlled, 2:1 randomization, n=24. Primary endpoint: NASA score at week 16. Secondary endpoints include pruritus/pain, infections, TEWL, microbiome, and skin biomarkers including protease markers. (NCT04244006 chunk 1) - Expert interpretation: case reports show variable benefit, often pruritus reduction; some responses may be transient. (pawlowski2024interleukin36ishighly pages 5-6)

Secukinumab (IL-17A) and combination biologic therapy - Real-world cohort/observational: NCT07151508 (completed; retrospective cohort; January 2021–June 2024) includes 15 pediatric NS patients treated with weight-adapted secukinumab and often add-on dupilumab (13 received combination therapy). Outcomes include ISS total score and biomarkers (IgE; IL-17A levels in CD4+ lymphocytes) with safety labs and AE recording, though results are not provided in the retrieved excerpt. (NCT07151508 chunk 1)

Broader biologic/JAK inhibitor landscape (expert synthesis) - A recent comprehensive therapeutics review emphasizes that targeted treatments remain largely limited to case reports and small series; dupilumab is most frequently reported, IL-17 blockade is rational for Th17/IL-36–dominant disease, and JAK inhibitors have been used in resistant cases. (morizane2025biologicsandsmall‐molecule pages 8-9)

  1. Statistics and data points from recent studies

Disease frequency - ~1:200,000 persons worldwide (Petrova 2024). (petrova2024comparativeanalysesof pages 1-2)

IgE values (clinical quantitative markers) - Moltrasio case: total IgE 200–1000 IU/mL (normal <120 IU/mL). (moltrasio2023nethertonsyndromecaused pages 2-5) - Pawlowski case: serum IgE 5251 kU/L. (pawlowski2024interleukin36ishighly pages 1-2)

Pathway quantitation - Transcriptomic DE calling used adjusted P<0.05 and |log2FC|>1 thresholds in Petrova 2024; immune signature lists IL17/IL36/IL22/IL23 and IL1 genes. (petrova2024comparativeanalysesof pages 6-7)

  1. Expert opinions and analysis (authoritative sources)

  2. Petrova et al. (2024) provides a conserved “molecular framework” and positions a KLK/IL-36 axis as a mechanistic and therapeutic target class, emphasizing shared human/mouse signatures and systemic inflammation correlations. (petrova2024comparativeanalysesof pages 1-2)

  3. Pawlowski et al. (2024) explicitly interprets their findings: “Data from this small case series further support the assertion that NS is, at least in part, driven by Th17 inflammation,” and notes IL-36 IHC’s diagnostic potential but limited specificity versus other Th17 dermatoses. (pawlowski2024interleukin36ishighly pages 5-6)

  4. Recent therapeutics reviews note the lack of approved targeted therapies and the heterogeneity of immunotypes, arguing for mechanistically stratified therapy (Th2 vs Th17/IL-36 vs IFN). (morizane2025biologicsandsmall‐molecule pages 7-8)

  5. Knowledge base–ready annotations (draft)

12.1 Pathophysiology description (narrative) Netherton syndrome (MONDO_0009735; OMIM #256500) is an autosomal recessive genodermatosis caused by SPINK5 loss-of-function, resulting in reduced functional LEKTI and loss of epidermal control over kallikrein-related proteases (KLKs). Unrestrained KLK activity degrades corneodesmosomal cadherins and lipid-processing enzymes, producing impaired cornification/keratinization, premature stratum corneum detachment, and barrier failure. Protease excess also activates PAR2 signaling and can proteolytically process inflammatory mediators (e.g., IL-1B, complement C3), inducing epithelial alarmins such as TSLP and inflammatory mediators (TNF-α, IL-8, ICAM-1). The downstream immune landscape includes mixed Th2 atopic and Th17 programs, with evidence for IL-17/IL-36 signatures in skin; IL-36 is robustly expressed in NS biopsies and may serve as an ancillary diagnostic marker. (petrova2024comparativeanalysesof pages 1-2, moltrasio2023nethertonsyndromecaused pages 1-2, pawlowski2024interleukin36ishighly pages 1-2)

12.2 Gene/protein annotations (HGNC) - SPINK5 (serine peptidase inhibitor Kazal type 5) → LEKTI; causal for NS. (moltrasio2023nethertonsyndromecaused pages 1-2) - KLK5, KLK6, KLK7, KLK13, KLK14: dysregulated epidermal serine proteases normally inhibited by LEKTI. (petrova2024comparativeanalysesof pages 1-2) - F2RL1 (PAR2): protease-activated receptor implicated in protease-driven inflammation/TSLP induction. (petrova2024comparativeanalysesof pages 1-2, moltrasio2023nethertonsyndromecaused pages 5-7)

12.3 Example GO biological processes disrupted - Proteolysis; keratinization; negative regulation of peptidase activity; immune/inflammatory response; desquamation. (petrova2024comparativeanalysesof pages 6-7, petrova2024comparativeanalysesof pages 22-22)

12.4 Cellular components - Lamellar granules (LEKTI localization) and extracellular stratum granulosum/stratum corneum interface. (pawlowski2024interleukin36ishighly pages 6-8)

12.5 Phenotype associations (HP-style; text-supported) - Ichthyosis/erythroderma and scaling; atopic diathesis/hyper-IgE; trichorrhexis invaginata (hair shaft defect). (moltrasio2023nethertonsyndromecaused pages 5-7, moltrasio2023nethertonsyndromecaused pages 2-5)

  1. Evidence items with PMIDs (limitations) The retrieved full-text excerpts did not consistently provide PubMed identifiers inline. Where PMIDs are requested, the key 2023–2024 mechanistic papers can be identified by DOI/URL in this report; PMIDs should be appended during curation using PubMed DOI→PMID mapping. (petrova2024comparativeanalysesof pages 1-2, pawlowski2024interleukin36ishighly pages 1-2, moltrasio2023nethertonsyndromecaused pages 1-2)

  2. Key references (with publication dates and URLs)

  3. Petrova E. et al. “Comparative analyses of Netherton syndrome patients and Spink5 conditional knock-out mice uncover disease-relevant pathways.” Communications Biology. Published Feb 2024. https://doi.org/10.1038/s42003-024-05780-y (petrova2024comparativeanalysesof pages 1-2)
  4. Pawlowski J. et al. “Interleukin-36 Is Highly Expressed in Skin Biopsies from Two Patients with Netherton Syndrome.” Dermatopathology. Published Aug 2024. https://doi.org/10.3390/dermatopathology11030024 (pawlowski2024interleukin36ishighly pages 1-2)
  5. Moltrasio C. et al. “Netherton Syndrome Caused by Heterozygous Frameshift Mutation Combined with Homozygous c.1258A>G Polymorphism in SPINK5 Gene.” Genes. Published May 2023. https://doi.org/10.3390/genes14051080 (moltrasio2023nethertonsyndromecaused pages 1-2)
  6. Clinical trial: NCT04244006 “A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome.” Start 2020-07-23; primary completion estimated 2024-06-01. https://clinicaltrials.gov/study/NCT04244006 (NCT04244006 chunk 1)

  7. Real-world cohort: NCT07151508 “Successful Treatment of Netherton Syndrome With Combination of Secukinumab and Dupilumab.” Observational; Jan 2021–Jun 2024. https://clinicaltrials.gov/study/NCT07151508 (NCT07151508 chunk 1)

  8. Included mechanistic figure

  9. Petrova et al. 2024, schematic summary of Spink5 cKO pathway changes (protease activity and immune/inflammatory programs). (petrova2024comparativeanalysesof media 61a4f2db)

References

  1. (moltrasio2023nethertonsyndromecaused pages 1-2): Chiara Moltrasio, Maurizio Romagnuolo, Davide Riva, Davide Colavito, Silvia Ferrucci, Angelo Marzano, Gianluca Tadini, and Michela Brena. Netherton syndrome caused by heterozygous frameshift mutation combined with homozygous c.1258a>g polymorphism in spink5 gene. Genes, 14:1080, May 2023. URL: https://doi.org/10.3390/genes14051080, doi:10.3390/genes14051080. This article has 5 citations.

  2. (petrova2024comparativeanalysesof pages 1-2): Evgeniya Petrova, Jesús María López-Gay, Matthias Fahrner, Florent Leturcq, Jean-Pierre de Villartay, Claire Barbieux, Patrick Gonschorek, Lam C. Tsoi, Johann E. Gudjonsson, Oliver Schilling, and Alain Hovnanian. Comparative analyses of netherton syndrome patients and spink5 conditional knock-out mice uncover disease-relevant pathways. Communications Biology, Feb 2024. URL: https://doi.org/10.1038/s42003-024-05780-y, doi:10.1038/s42003-024-05780-y. This article has 13 citations and is from a peer-reviewed journal.

  3. (moltrasio2023nethertonsyndromecaused pages 5-7): Chiara Moltrasio, Maurizio Romagnuolo, Davide Riva, Davide Colavito, Silvia Ferrucci, Angelo Marzano, Gianluca Tadini, and Michela Brena. Netherton syndrome caused by heterozygous frameshift mutation combined with homozygous c.1258a>g polymorphism in spink5 gene. Genes, 14:1080, May 2023. URL: https://doi.org/10.3390/genes14051080, doi:10.3390/genes14051080. This article has 5 citations.

  4. (petrova2024comparativeanalysesof pages 6-7): Evgeniya Petrova, Jesús María López-Gay, Matthias Fahrner, Florent Leturcq, Jean-Pierre de Villartay, Claire Barbieux, Patrick Gonschorek, Lam C. Tsoi, Johann E. Gudjonsson, Oliver Schilling, and Alain Hovnanian. Comparative analyses of netherton syndrome patients and spink5 conditional knock-out mice uncover disease-relevant pathways. Communications Biology, Feb 2024. URL: https://doi.org/10.1038/s42003-024-05780-y, doi:10.1038/s42003-024-05780-y. This article has 13 citations and is from a peer-reviewed journal.

  5. (pawlowski2024interleukin36ishighly pages 1-2): Johannes Pawlowski, Tatsiana Pukhalskaya, Kelly Cordoro, Marina Kristy Ibraheim, and Jeffrey P. North. Interleukin-36 is highly expressed in skin biopsies from two patients with netherton syndrome. Dermatopathology, 11:230-237, Aug 2024. URL: https://doi.org/10.3390/dermatopathology11030024, doi:10.3390/dermatopathology11030024. This article has 2 citations.

  6. (pawlowski2024interleukin36ishighly pages 5-6): Johannes Pawlowski, Tatsiana Pukhalskaya, Kelly Cordoro, Marina Kristy Ibraheim, and Jeffrey P. North. Interleukin-36 is highly expressed in skin biopsies from two patients with netherton syndrome. Dermatopathology, 11:230-237, Aug 2024. URL: https://doi.org/10.3390/dermatopathology11030024, doi:10.3390/dermatopathology11030024. This article has 2 citations.

  7. (moltrasio2023nethertonsyndromecaused pages 2-5): Chiara Moltrasio, Maurizio Romagnuolo, Davide Riva, Davide Colavito, Silvia Ferrucci, Angelo Marzano, Gianluca Tadini, and Michela Brena. Netherton syndrome caused by heterozygous frameshift mutation combined with homozygous c.1258a>g polymorphism in spink5 gene. Genes, 14:1080, May 2023. URL: https://doi.org/10.3390/genes14051080, doi:10.3390/genes14051080. This article has 5 citations.

  8. (kline2024staphylococcusaureusproteases pages 1-2): Sabrina N. Kline, Yoshine Saito, and Nathan K. Archer. staphylococcus aureus proteases: orchestrators of skin inflammation. DNA and Cell Biology, 43:483-491, Oct 2024. URL: https://doi.org/10.1089/dna.2024.0134, doi:10.1089/dna.2024.0134. This article has 4 citations and is from a peer-reviewed journal.

  9. (morizane2025biologicsandsmall‐molecule pages 8-9): Shin Morizane, Tomoyuki Mukai, Ko Sunagawa, Ken‐ichi Hasui, Anri Morita, Hayato Nomura, and Mamoru Ouchida. Biologics and small‐molecule therapies in netherton syndrome: a comprehensive review. The Journal of Dermatology, 52:1483-1493, Sep 2025. URL: https://doi.org/10.1111/1346-8138.17923, doi:10.1111/1346-8138.17923. This article has 1 citations.

  10. (NCT07151508 chunk 1): Successful Treatment of Netherton Syndrome With Combination of Secukinumab and Dupilumab. Federal Research Institute of Pediatric Hematology, Oncology and Immunology. 2023. ClinicalTrials.gov Identifier: NCT07151508

  11. (pawlowski2024interleukin36ishighly pages 6-8): Johannes Pawlowski, Tatsiana Pukhalskaya, Kelly Cordoro, Marina Kristy Ibraheim, and Jeffrey P. North. Interleukin-36 is highly expressed in skin biopsies from two patients with netherton syndrome. Dermatopathology, 11:230-237, Aug 2024. URL: https://doi.org/10.3390/dermatopathology11030024, doi:10.3390/dermatopathology11030024. This article has 2 citations.

  12. (pawlowski2024interleukin36ishighly pages 2-5): Johannes Pawlowski, Tatsiana Pukhalskaya, Kelly Cordoro, Marina Kristy Ibraheim, and Jeffrey P. North. Interleukin-36 is highly expressed in skin biopsies from two patients with netherton syndrome. Dermatopathology, 11:230-237, Aug 2024. URL: https://doi.org/10.3390/dermatopathology11030024, doi:10.3390/dermatopathology11030024. This article has 2 citations.

  13. (petrova2024comparativeanalysesof pages 22-22): Evgeniya Petrova, Jesús María López-Gay, Matthias Fahrner, Florent Leturcq, Jean-Pierre de Villartay, Claire Barbieux, Patrick Gonschorek, Lam C. Tsoi, Johann E. Gudjonsson, Oliver Schilling, and Alain Hovnanian. Comparative analyses of netherton syndrome patients and spink5 conditional knock-out mice uncover disease-relevant pathways. Communications Biology, Feb 2024. URL: https://doi.org/10.1038/s42003-024-05780-y, doi:10.1038/s42003-024-05780-y. This article has 13 citations and is from a peer-reviewed journal.

  14. (petrova2024comparativeanalysesof media 61a4f2db): Evgeniya Petrova, Jesús María López-Gay, Matthias Fahrner, Florent Leturcq, Jean-Pierre de Villartay, Claire Barbieux, Patrick Gonschorek, Lam C. Tsoi, Johann E. Gudjonsson, Oliver Schilling, and Alain Hovnanian. Comparative analyses of netherton syndrome patients and spink5 conditional knock-out mice uncover disease-relevant pathways. Communications Biology, Feb 2024. URL: https://doi.org/10.1038/s42003-024-05780-y, doi:10.1038/s42003-024-05780-y. This article has 13 citations and is from a peer-reviewed journal.

  15. (NCT04244006 chunk 1): A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome. University Hospital, Toulouse. 2020. ClinicalTrials.gov Identifier: NCT04244006

  16. (morizane2025biologicsandsmall‐molecule pages 7-8): Shin Morizane, Tomoyuki Mukai, Ko Sunagawa, Ken‐ichi Hasui, Anri Morita, Hayato Nomura, and Mamoru Ouchida. Biologics and small‐molecule therapies in netherton syndrome: a comprehensive review. The Journal of Dermatology, 52:1483-1493, Sep 2025. URL: https://doi.org/10.1111/1346-8138.17923, doi:10.1111/1346-8138.17923. This article has 1 citations.